Body fluid sampling arrangements

Information

  • Patent Grant
  • 10842427
  • Patent Number
    10,842,427
  • Date Filed
    Friday, December 1, 2017
    6 years ago
  • Date Issued
    Tuesday, November 24, 2020
    3 years ago
Abstract
An arrangement for producing a sample of body fluid from a wound opening created in a skin surface at a sampling site includes at least one skin-penetration member having a first end configured to pierce the surface of the skin, and a inner lumen in communication with the first end; at least one actuator operatively associated with the at least one skin-penetration member; and at least one catalyst device configured to cause perfusion of body fluid at the sampling site; wherein the at least one actuator is configured to locate the at least one skin-penetration member so as to obstruct the wound opening while transporting body fluid through the inner lumen. Associated methods are also described.
Description
FIELD

The present invention relates to devices, arrangements and methods involving body fluid sampling with the assistance of a catalyst. In certain embodiments, the present invention is directed to integrated monitoring and body fluid sampling and monitoring devices and methods that permit both digital and alternative-site body fluid sampling and analysis.


BACKGROUND

In the discussion that follows, reference is made to certain structures and/or methods. However, the following references should not be construed as an admission that these structures and/or methods constitute prior art. Applicants expressly reserve the right to demonstrate that such structures and/or methods do not qualify as prior art.


According to the American Diabetes Association, diabetes is the fifth-deadliest disease in the United States and kills more than 213,000 people a year, the total economic cost of diabetes in 2002 was estimated at over $132 billion dollars. One out of every 10 health care dollars is spent on diabetes and its complications. The risk of developing type I juvenile diabetes is higher than virtually all other chronic childhood diseases. Since 1987 the death rate due to diabetes has increased by 45 percent, while the death rates due to heart disease, stroke, and cancer have declined.


A critical component in managing diabetes is frequent blood glucose monitoring. Currently, a number of systems exist for self-monitoring by the patient. Most fluid analysis systems, such as systems for analyzing a sample of blood for glucose content, comprise multiple separate components such as separate lancing, transport, and quantification portions. These systems are bulky, and often confusing and complicated for the user. The systems require significant user intervention.


Technology development in the field of self-monitoring of blood glucose has placed the burden of acquiring sufficient blood for conducting a test on the user of the technology. Historically, diabetics have been taught to lance their finger tips to produce blood for conducting the test. Ironically, the fingers are not only one of the most sensitive body parts to pain, but they also are among the areas of skin that are most highly perfused with blood. Earlier versions of consumer-oriented self-monitoring products usually required many microliters of blood, and the finger tips provided a reasonably convenient area to lance that would be most likely to produce the required volume of blood.


More recently, some self-monitoring systems offer the option to the user to test at alternate sites such as the palm, forearm, or thigh. While these sites are generally known to be significantly less sensitive to the pain associated with lancing, the adoption of alternate site testing has been limited for at least four reasons: (1) only a few meter products have been approved by the FDA for testing at alternate sites at this time; (2) many testers do not know that they can use their device at the alternate sites; (3) many testers find it relatively difficult to express sufficient blood at the alternate sites to perform a test; (4) data published in medical literature on some of the meters shows that there may be a distinct difference between glucose levels measured at alternate sites relative to the finger, particularly when glucose levels are falling and/or the subject may be hypoglycemic. Consequently, there is a perception by the medical community that there may be an increased risk for delayed or improper treatment by the diabetic if they act only on the basis of glucose levels measured from alternate sites. Thus, the finger lancing site remains the most frequently used test site by far.


Lancing devices and the lancets themselves have also evolved somewhat over the past few decades. Some lancing mechanisms may produce relatively less pain by either (1) projecting the lancet in and out of the skin in a more straight path and thus reducing stimulation of percutaneous nerves which provide the pain stimulus; and (2) offering depth control in the lancing device so that the user may balance the expression of sufficient blood against the level of pain. Furthermore, lancet manufacturers offer a variety of lancet sizes, lengths, and tip bevel patterns with some companies claiming that their lancet is less painful than others.


What remains clear is that the most testers, when lancing at the finger, often must put down the lancing device and apply pressure near the finger tip in order to produce sufficient blood for the test strip in the meter. Many instructions for use with conventional meter systems specifically prescribe that the user perform this “milking” process because without it, many will not spontaneously produce the required volume. Applicants have observed this phenomenon in the use of commonly available commercial sampling and meter systems. In a recent study, when a trained professional lanced the finger tips of 16 volunteer diabetic subjects at the maximum depth setting on commercially available device under controlled conditions, only 15% of lanced sites spontaneously produced sufficient blood for the meter to accurately measure glucose levels.


Attempts have been made in the past to take steps toward automation of the testing process at alternate sites. Specifically, the Sof-Tact® System offered by Medisense in the early 2000s had the capability to test automatically at alternate sites without any user intervention, but only after each lancet and test strip had been manually loaded into the device. This meter is no longer available on the market.


A device similar to the Soft-Tact® device is disclosed in U.S. Patent Application Publication No. 2004/0138588 A1. This device attempts to integrate all the functions required to complete a glucose test into one device. This device however still requires the user to load a lancet and a test strip prior to each individual testing event, and fails to describe a catalyst (i.e.—mechanism to stimulate or enhance expression of blood from the lanced wound site) that ensures that a sufficient sample is expressed from the wound.


The device is described in U.S. Patent Application Publication No. 2005/0010134 A1, and U.S. Pat. No. 6,793,633 B2 uses a spring, or motor driven mechanism, to apply pressure around the target wound area. From the description it appears that the user must insert a new lancet and test strip assembly for each test.


Another disadvantage with conventional arrangements such as the ones referenced above is that they involve complex and sometimes ineffective mechanisms for tranferring blood or body fluid from the wound to a remote location for analysis. For example, many conventional arrangements and techniques utilize a solid lancet for creating a wound in the surface of the skin. After piercing the skin the lancet is retracted and a separate member, such as a tube, is positioned to transfer the blood or body fluid. Alternatively, an absorbent test strip is moved into position, manually or in an automated fashion, so that it absorbs the sample of blood or body fluid from the wound site. These arrangements and techniques are overly complex, and clearly rely upon the precise positioning of the tube or test strip to transfer the sample of blood or body fluid. When seeking to automate the sampling process, this precise positioning requires rather complex mechanical arrangements and controls that must operate under close tolerances. Such complex systems and arrangements are either costly, unreliable, or both.


Thus, conventional sampling devices and methods are overly reliant upon user intervention, such as milking, in order to consistently express a sufficient quantity of blood from the wound site, or are overly complex and/or lack reliability.


Moreover, while many diabetics continue to test their blood glucose levels with blood from the finger, testing at the alternate sites offers the advantage of significantly less pain when lancing the palm, forearm, etc. Thus, it would be advantageous to have an automatic and fully integrated meter constructed for sampling and/or testing at either the finger and the alternate sites.


SUMMARY OF THE INVENTION

According to the present invention, there are provided body fluid sampling and monitoring devices and methods that may address one or more of the shortcomings noted above associated with conventional systems and devices. According to the present invention, there may also be provided improved body fluid sampling and monitoring devices and methods that enable both digital and alternative-site body fluid sampling without significant user intervention.


As used herein “digital” means fingers or toes. “Digital body fluid” means expression of body fluid from a wound created on the fingers or toes, and encompasses lancing sites on the dorsal or palm side of the distal finger tips.


As used herein “alternate site” means a location on the body other than the digits, for example, the palm, forearm or thigh. “Alternate-site body fluid sampling” means expression of body fluid from the lancing site on a surface of the body other than the fingers or toes, and encompasses lancing sites on the palm, forearm, and thigh.


As used herein, “body fluid” encompasses whole blood, intestinal fluid, and mixtures thereof.


As used herein “integrated device” or “integrated meter” means a device or meter that includes all components necessary to perform sampling of body fluid, transport of body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid.


As used herein, the term “obstructed opening” means that the needle or skin piercing element is not retracted prior to extracting the body fluid from the wound created thereby. Thus, for example, the portion of the opening or wound on or just below the surface of the skin is at least partially obstructed by the skin piercing member or needle which will be located at the wound opening entrance on or just below the surface of the skin upon extraction of body fluid. This aspect of the present invention is believed to run counter to the conventional wisdom in the art. See, for example, U.S. Pat. No. 6,063,039.


According to one aspect, the present invention is directed to an arrangement for producing a sample of body fluid from a wound opening created in a skin surface at a sampling site, the arrangement comprising: at least one skin-penetration member having a first end configured to pierce the surface of the skin, and a inner lumen in communication with the first end; at least one actuator operatively associated with the at least one skin-penetration member; and at least one catalyst device configured to enhance perfusion of body fluid at the sampling site;


wherein the at least one actuator is configured to locate the at least one skin-penetration member so as to obstruct the wound opening while transporting body fluid through the inner lumen.


According to another aspect, the present invention is directed to a method of sampling body fluid from a wound opening created in a skin surface at a sampling site, the method comprising: automatically or manually initiating a testing sequence; applying a catalyst to the sampling site; actuating a skin-piercing member so as to drive the member into the surface of the skin thereby creating the wound opening; allowing the at least one skin-penetration member to obstruct the wound opening; and transporting body fluid through an inner lumen of the skin-penetration member; wherein the catalyst is applied to the sampling site at one or more of the following times: prior to actuating the skin-piercing member, during actuation of the skin-piercing member, or after actuating the skin-penetration member.





BRIEF DESCRIPTION OF THE DRAWING FIGURES

The following description of preferred embodiments can be read in connection with the accompanying drawings in which like numerals designate like elements and in which:



FIG. 1 is a partial perspective view of an arrangement constructed according to the present invention.



FIG. 2 is a partial cut away side view of the arrangement of FIG. 1.



FIG. 3 is a partial cut away side view of the arrangement of FIG. 1, with an activated catalyst.



FIG. 4 is a partial cut away magnified side view of the arrangement of FIG. 1, with an activated catalyst and illustrating a mechanism of body fluid collection and transport according to the present invention.



FIG. 5 is a perspective view of a portion of an arrangement, including an actuator, constructed according to the present invention.



FIG. 6 is a perspective view of an integrated device formed according to one embodiment of the present invention.



FIG. 7 is a partial side view of the integrated device of FIG. 6.



FIG. 8 is a perspective view of a component of the integrated device of FIG. 6.



FIG. 9 is a partial perspective view of various components of the integrated device of FIG. 6.



FIG. 10 is a side view illustrating various additional components of the device of FIG. 6.



FIG. 11 is a perspective view of an integrated device formed according to an alternative embodiment of the present invention.





DETAILED DESCRIPTION

According to a first aspect of the present invention, there are provided arrangements and techniques for reliably expressing body fluid from a digit or from an alternate site. For example, according to the present invention, arrangements and techniques are provided which consistently and reliably express an amount of body fluid that is sufficient to perform an analysis to quantify the amount of an analyte (e.g., glucose, bilirubin, alcohol, controlled substances, toxins, hormones, proteins, etc.) contained therein.


One embodiment of an arrangement 10 of the type described above is illustrated in FIGS. 1-4. As illustrated therein, the arrangement 10 may include a housing 12. The housing 12 may have any suitable shape or configuration, and is not limited to the shape and configuration illustrated. The housing 12 can be constructed of any suitable material. For example, the housing 12 may be constructed of a polymeric or metallic material.


The arrangement 10 may further include a catalyst to assist in the sample acquisition process by enhancing perfusion of blood or body fluid at a sampling site. At least one of several catalysts may be utilized or included in the arrangement of the present invention. Possible catalysts include, lancing velocity, heat, pressure, vacuum, vibration, and topical drugs (which induce vasodilatation and increases the blood or body fluid available at the lancing site). These catalysts may be applied before, during, after lancing, or in combination with some or all three to facilitate expression of sufficient quantity of body fluid for determination of the concentration of an analyte contained therein (e.g., glucose).


Lancing velocity refers to the speed at which the skin piercing member is driven. Velocities ranging from ˜0-22 m/s are possible. Both pain and blood production may increase as velocity increases. Attempts to balance pain and blood have led to a preferred range of about 3-20 m/s, 3-10 m/s, or 10-12 m/s.


Pressure is another possible catalyst. Footprint contact pressure can be varied by a number of possible techniques. One such technique is to vary the size of the opening of the footprint. Another form of pressure catalyst can take the form of a pressure-applying member that circumferentially surrounds and squeezes the digit or other body part from which a sample is to be acquired. One illustrative example of this form of catalyst is a pressure-applying cuff-like member of the type described in U.S. patent application Ser. No. 14/510,784 entitled BODY FLUID MONITORING AND SAMPLING DEVICES AND METHODS, the entire content of which is incorporated herein by reference. The above-described pressure catalyst can be utilized alone, or in combination with other catalysts such as vacuum pressure.


Heat is another optional catalyst. Increasing heat, thereby increasing the skin temperature at the wound site, increases blood production. Possible implementations of heat include IR lights, or resistive elements to heat the skin.


Another catalyst is vacuum pressure. According to certain embodiments, a light vacuum (e.g., 3-8 in. Hg) is applied to the wound site before, during, and/or after lancing. Several embodiments for applying vacuum to the wound site are contemplated. One embodiment uses a motor driven pump to apply vacuum. Alternative embodiments include using individually packaged vacuum chambers to apply vacuum, or using a rigid syringe like mechanism to apply vacuum. Other systems use motor driven pumps and syringes.


According to the principles of the present invention, one or more of the above-described catalysts can be used in combination with each other, either concurrently or sequentially.


In certain specific embodiments of the arrangement 10, a catalyst device 14 can be included which comprises a member or combination of members for applying pressure to a surface of the skin S disposed at a location which is proximate to an area from which a sample of body fluid is to be expressed (i.e., sampling site 28). The catalyst device 14 may cause the area of the skin from which the sample of body fluid is to be expressed to become perfused with blood and/or body fluid. This effect facilitates expression of body fluid from a wound opening 30. According to the illustrated embodiment, the catalyst device 14 comprises a member or combination of members, such as the illustrated pump 16 and related controller 18.


The arrangement 10 further comprises a footprint 20 which is attached to the housing 12. According to the illustrated embodiment, a digit D is placed on the footprint 20 at the sampling site. However, it should be understood that the footprint may also be applied to the surface of the skin at an alternate site. The footprint 20 has a central opening and may optionally have an annular in shape. However, the footprint is not limited to this shape or configuration. Numerous shapes or configurations may satisfy the function of providing a footprint around the site from which body fluid is to be expressed. The footprint can have an opening of any suitable diameter or major dimension 21. According to an illustrative example, the diameter or major dimension is at least about 3-8 mm. According to certain embodiments, the footprint 20 is constructed from a material which facilitates the formation of a seal between the digit D and the footprint 20. For example, suitable materials for this purpose include a relatively soft elastomeric material, such as a silicone rubber.


The arrangement 10 further includes at least one skin penetration member 22. The at least one skin penetration member 22 can take any suitable form. For example, the at least one skin penetration member can comprise a solid lancet or a hollow needle. Conventional arrangements often require separate mechanisms for drawing a sample of blood to the surface of the skin and for transporting the sample to a reaction chamber. The device of the present invention can use a skin-piercing element in the form of a hollow needle to both create and transport the sample, thereby greatly simplifying and improving the effectiveness of the arrangement 10. According to one optional embodiment, the skin-penetration member(s) 22 can be in the form of a so-called “microneedle.” As the name implies, microneedles are characterizable by their relatively small outer diameters. For example, a microneedle, as the term is utilized herein, may encompass a skin-penetration member having an outside diameter which is on the order of 40-200 μm. The inside diameter can vary, for example, having an inside diameter on the order of 25-160 μm. Needles are also characterizable in the art by reference to the “gage.” By way of illustration, and consistent with the above description, microneedles having a gage ranging from 26-36 are clearly comprehended by the present invention. Certain advantages may be gleaned from the use of such microneedles as the skin-penetration member. In particular, due to their small size, the size of the wound left upon entry into the skin is relatively small, thereby minimizing the pain associated with such needle insertions and allowing for a quicker healing process. However, the present invention is certainly not limited to the use of such microneedles. Thus, for example, according to one possible alternative embodiment, the skin penetration member(s) comprise hollow needles having a gage of about 20-25, or comprising hollow needles having an inner diameter of about 0.007 inches and an outer diameter of about 0.020 inches.


The at least one skin-penetration member 22 can be formed of any suitable material, such as metal, plastic, glass, etc. Optionally, the at least one skin penetration member can be mounted to a hub 24. In further alternative embodiments, the hub 24 may contain an assay pad 34 comprising a reagent that changes color upon reaction with a target analyte, as known per se to those skilled in the art. As illustrated, for example, in FIG. 2, the skin-penetration member 22 and hub 24 may be located within a chamber 25. The chamber 25 is in communication with pump 16 so that vacuum pressure can be applied within the chamber 25. The arrangement 10 can comprise a plurality of skin penetration members 22. According to certain embodiments, the plurality of skin penetration members 22 can be provided in the form of a replaceable cartridge. The at least one skin penetration member 22, and/or the hub 24 are attached to an actuation element 26. The actuation element 26 can take any suitable form. For example, the actuation element 26 may comprise a mechanical, electrical or pneumatic element. According to the illustrated embodiment, the actuation element 26 is in the form of a mechanical spring, more specifically, in the form of a torsional spring.


According to certain embodiments of the present invention, the catalyst device 14 operates in an automatic or semi-automatic manner. For example, a user may place the footprint 20 over a surface of the skin on a digit D, or at an alternate site. When the user is ready to produce a sample of body fluid, the button B is pressed. This can initiate a programmed sequence of events in the device including actuation of the catalyst device 14, thereby applying vacuum pressure to the skin an area proximate the tip region of digit D or alternate sampling site (FIG. 3) for a predetermined period of time. The skin-penetration member 22 can then be driven into the skin (FIG. 4). At a predetermined time, the catalyst device 14 is deactivated. This mode of operation can be characterized as “semi-automatic” in that sequence of events must be manually initiated by the user via pressing the button B.


According to one alternative, the mode of operation can be fully automatic. For example, the user places a tip region of digit D on the footprint 20, or places the footprint over an alternate site. The arrangement 10 can be provided with one or more sensors 27 that detect and verify that the footprint is properly located and ready for the sampling procedure to begin. Once this state has been sensed, the device automatically activates the catalyst 14 which is applied to the skin at the sampling site 28 (FIG. 3) for a predetermined period of time. Subsequently, the at least one skin penetration member 22 is driven into the skin (FIG. 4). At a subsequent predetermined time, the catalyst device 14 is deactivated. The catalyst device can be deactivated before, during or after the skin-piercing member is driven into the skin.


The arrangement 10 can form at least part of a device which functions only to sample body fluid. For example, the arrangement 10 can be used to express body fluid from the skin in the form of a drop of blood which pools on the surface of the skin of the user. This drop of blood can then be transferred to another separate device which then transports and/or analyzes the sample for a target analyte. Alternatively, the arrangement 10 may express a sample of body fluid from the skin, and then transport the sample to a location which can then be accessed for further analysis by a separate device. For instance, the sample body fluid can be transported to a reagent-containing pad 34, also contained within the arrangement 10. The sample then reacts with the reagent to produce a detectable spot or signal. The reagent pad can then be analyzed by a separate meter using photochemical, electrochemical, or other suitable techniques known per se to those skilled in the art. The reagent pad can remain within the arrangement 10 during the aforementioned analysis. According to an alternative embodiment, the reagent pad 34 can be analyzed by a detector 36 that forms part of the arrangement 10. Alternatively, the reagent pad can be removed from the arrangement 10 and inserted into a separate device, such as an electrochemical or photometric meter.


As illustrated, for example, in FIG. 4, according to this optional aspect of the present invention a skin-piercing member 22 in the form of a needle having a first end 22e configured to pierce the skin and an inner lumen 22l is driven into the skin to create a wound opening 30 therein for producing a sample of body fluid 32, preferably blood. The needle is not retracted right away, instead it is allowed to dwell and obstruct the opening 30 created in the surface of the skin. Blood or body fluid 32 is then extracted and flows through the inner lumen 22l of the needle, and is eventually transported to a site within the arrangement 10 for further analysis. The blood or body fluid 32 is drawn though the inner lumen by any suitable mechanism, such as capillary action, vacuum, or a combination of both. The needle 22 may be caused to dwell at the desired location via any of the mechanisms described herein. The skin-piercing member 22 is eventually retracted (see, e.g., FIG. 2). It has been surprisingly observed that an adequate sample volume can be extracted by the above-described arrangement/technique, especially when utilizing a vacuum catalyst. This arrangement and technique is advantageous in that a skin piercing member 22 may be used for wound creation and sample transport. Complex mechanisms and arrangements for repositioning a transport member or assay pad to a location that does not obstruct the opening can be avoided. Other advantages of obstructed opening sampling is realizing a reduction in the required sample volume, and improving the reliability of obtaining an adequate sample. When the needle is located so as to obstruct the wound opening, the end of the needle is closer to the source of body fluid, thus smaller drops of sample are more likely to reach the inner lumen of the needle and be successfully transported as the needle rests on or in the skin. By contrast, when the needle is withdrawn away from the surface of the skin, as in conventional arrangements and techniques, the droplet of blood or body fluid must be significantly larger/taller to reach the end of the needle and lumen, thereby elevating the risk that an insufficient sample is obtained.


As illustrated in FIG. 5, each individual skin-piercing element 22 is provided with its own actuation element or torsional spring 26. The torsional spring elements 26 may be provided to the user in a pre-cocked position. The acceleration path of the skin-piercing element or needle 22 may begin up to 180 degrees from the angle of impact with the skin S of the user. According to one beneficial aspect, the pivot point of the torsional spring elements can be provided as close as possible to the plane lying on the surface of the skin S in order to ensure that the skin piercing element 22 strikes the skin at an angle which is as close to 90 degrees as possible. The torsional spring element 26 can act as a guide for the skin-piercing element or needle 22 to that locates the tip 22e thereof so as to obstruct the wound opening 30 so as to draw the blood 32 into the lumen 22l of the needle. In this regard, the torsional spring element 26 may be designed such that its neutral position Ro will locate the needle so as to obstruct the wound opening 30 created by the skin piercing operation.


Another advantage of this optional aspect of the present invention is that the torsional spring elements 26 do not require a positive stop to limit the penetration depth of the skin-piercing element 22. It has been observed that elimination of a hard stop may provide certain beneficial effects. Namely, it has been observed that devices that include a hard stop experience a shock and resulting vibration and/or stirring action when the stop is impacted. It is theorized that this motion may increase the observable wound and/or the perceived pain associated with sampling. According to this embodiment, the depth of penetration of the skin-penetrating member 22 is determined by a number of factors, including the design of the sharp, the actuation force and the skin's resistance to penetration at the chosen sampling site. The lack of a positive stop has not been observed as increasing pain in clinical studies.


An exemplary body fluid sampling method or technique which may be used in conjunction with any of the above-described arrangements, but is not necessarily limited thereto, is described as follows.


A footprint is placed over a sampling site located on a digit or at an alternate site. The footprint has an opening therein which defines the sampling site. A sequence of events is then initiated. The events can be initiated manually, for example, by pressing a button or other triggering mechanism. Alternatively, the events can be automatically triggered, for example, through the use of sensors which determine when the footprint has been property positioned over a sampling site on the surface of the skin. A catalyst is then applied to the sampling site. The catalyst can comprise one or more of lancing velocity, heat, pressure, vacuum, vibration, topical drugs, or combinations thereof. These catalysts can be applied concurrently or sequentially relative to one another. According to one embodiment, a catalyst in the form of vacuum pressure is applied to the sampling site via a suitable mechanism, such as a pump capable of creating vacuum pressure. The catalyst can be applied for a set period of time, and then removed or terminated. For example, the catalyst can be removed before, during, or after penetration of the skin. Next, at least one skin penetration member is actuated or driven into the surface of the skin. The skin penetration member can take any suitable form, such as a solid lancet or hollow needle (e.g., a microneedle). According to one embodiment, at least one skin penetration member comprises a hollow needle having a first end configured to pierce the surface of the skin, and an inner lumen. The at least one skin penetration member can be actuated via any suitable mechanism, such as a mechanical spring. According to one optional embodiment, the actuating mechanism comprises a torsional spring. The at least skin penetration member is caused to dwell at or below the surface of the skin in the vicinity of the wound opening in order to obstruct the same. The skin penetration member can be caused to dwell at this location via any suitable mechanism. According to one embodiment, the actuator is provided in the form of a torsional spring having a resting position which can be utilized to cause the first end of the at least one skin penetration member to obstruct the wound opening subsequent to piercing the surface of the skin. During the period of time in which the at least one skin penetration member is caused to dwell at the wound opening, body fluid is transported away from the wound site via a suitable mechanism. According to one embodiment, the body fluid, or blood, is transported via the inner lumen of a hollow skin-penetration member via capillary action, vacuum, or a combination of both. According to one optional embodiment of the present invention, a mechanism can be provided which estimates the acquired sample volume, and compares this measured sample volume with a target sample volume. The information acquired by this analysis can be used to control the catalyst such that it is automatically removed once the target sample volume has been acquired. Any suitable mechanism can be utilized to analyze the acquired sample volume. For example, the body fluid can be transported to an assay pad which contains a chemical reagent impregnated therein. Upon exposure to the body fluid, a target analyte contained therein causes a chemical reaction producing a color change in the assay pad. This color change can in turn be detected by a suitable detection element. One such detection element utilizes colorimetric optical analysis of the assay pad. More specifically, an array of such detection elements can be provided along a longitudinal length of the assay pad. The number of detection elements contained along the length of the assay pad that detect the presence of the sample can be correlated to the acquired sample volume. For example, the further the sample volume travels along the length of the assay pad the greater the acquired sample volume. Once it has been determined that a target sample volume has been acquired, the catalyst can then be terminated. This can be accomplished by the use of a controller in signal communication with a pump. The controller operates based on signals derived from the analysis of the sample volume in the manner described above. Some advantages of monitoring volume to actively control the application of the catalyst include reduction in expression of excess blood or body fluid thereby reducing mess, preventing damage to skin (bruising, etc) due to prolonged catalyst application, and reduction in power consumption.


According to a further optional aspect of the present invention, the above-described arrangements and methods can form at least part of an integrated device or integrated meter. As previously noted, as used herein, the term “integrated device” or “integrated meter” means a device or meter that includes all components necessary to perform sampling of the body fluid, transport of the body fluid, quantification of an analyte, and display of the amount of analyte contained in the sample of body fluid. Thus, according to the principles of the present invention, an integrated device or meter can comprise one or more, or any combination, of the features previously described herein. According to further aspects of the present invention, and integrated meter or device can comprise components and/or features in addition to those specifically described herein.


An exemplary integrated meter is illustrated in detail in FIGS. 6-10. As illustrated therein, the integrated meter 100 generally comprises a housing 112 and a catalyst device 114 (e.g., FIG. 10). The catalyst device 114 may take any suitable form and can comprise any of the previously described alternative catalyst devices. The integrated meter 100 may further comprise a footprint 120 of the type previously described. A door 123 can be provided on the housing 112. The door 123 is connected via a hinge 125 to the housing 112. As described in further detail below, the door 123 can be opened to reveal a cartridge 131 containing a plurality of skin-piercing elements 122. In the illustrated embodiment, the integrated meter 100 further includes a display 127 for communicating the results of the analysis on the sample body fluid for the presence and/or concentration of an analyte contained therein. The integrated meter 100 may further include one or more buttons 129 which can be pressed by the user to engage various functions and interfaces of the integrated meter 100.



FIG. 7 is an illustration of the integrated meter 100 with the door 123 opened to reveal further details of the interior components of the exemplary integrated meter 100. As illustrated therein, the housing 112 contains a cartridge 131 therein. In the illustrated embodiment, the cartridge 131 is circular and contains a plurality of skin-piercing elements as further described herein. The cartridge 131 is mounted about a hub 133 and is rotatable. Thus, upon sampling a skin-piercing element 22 is driven through an opening in the housing in registry with the footprint 120 and pierces the skin of the user. Once the test has been completed, the cartridge 131 can be rotated such that an unused skin-piercing element now comes into registry with the opening in the housing and the corresponding opening in the footprint 120 in preparation for the next sampling event. It should be understood that the present invention is not limited to the illustrated circular cartridge having the particular configuration depicted in the drawing figures. To the contrary, a number of alternative cartridge configurations are possible, such as a slidable linear or polygonal configuration (not shown). Also illustrated in FIG. 7 is the presence of a light source 139 disposed on the back of the door 123. The light source 139 can take any suitable form, such as a light emitting diode. It should be understood that alternative light sources may also be utilized. The function of the light source 139 will be described in further detail below.


Further details of the optical assembly 135, the light source 139, and the replaceable cartridge 131 are illustrated in FIGS. 8-9. As illustrated therein, the replaceable cartridge 131 generally may comprise a plurality of compartments defining a plurality of body fluid sampling and analysis sites 132. Contained in each sampling and analysis site 132 is a skin penetration member 122. Each skin penetration member 122 can take any suitable form. According to the illustrated embodiment, each skin penetration member 122 is in the form of a hollow needle. It should be understood that alternative skin penetration members may also be utilized consistent with the principles of the present invention (e.g., solid lancets, etc.) each skin-penetration member can be attached to a needle hub 124. Each needle hub 124 is, in turn, attached to an actuation element 126. It should be understood that a number of different actuation elements may be utilized according to the principles of the present invention. The actuation elements can be mechanical, electrical, pneumatic, etc. According to the illustrated embodiment, the actuation element 126 is in the form of a torsional spring and may have those features and characteristics previously described herein. Upon activation, the torsional spring drives the needle hub 124 and the attached skin penetration member 122 into the skin of the user disposed on the footprint 120. According to certain embodiments, each sampling/analysis site 132 further contains a signaling mechanism which produces a detectable signal when contacted with a target analyte contained in a sample of body fluid expressed from the skin. A number of suitable mechanisms are envisioned. The mechanisms may be based on technologies such as photometric or electrochemical analysis. According to the illustrated embodiment, each needle hub 124 contains a reagent pad 129 which generally comprises an absorbent material containing a chemical reagent which, upon reaction with a target analyte, produces a chemical reaction that results in a detectable signal. The reagent pad 129 is in fluid communication with the inner lumen of the skin piercing element 122. As noted above, the signal can be detected optically, electrochemically, or by other suitable means. According to one embodiment, the reagent pad 129, upon reaction with the target analyte, produces a spot which is optically detected by the optical assembly 135 in a manner generally known to those skilled in the art. The spot produced by the above-mentioned reaction can be observed optically through a window 143 formed along the interior region of the illustrated cartridge 131 by the optical assembly 135. In this regard, light emitted from the light source 139 is incident upon the reagent pad 129, and reflects off the surface thereof. Upon formation of a reaction spot on the surface of the reagent pad 129, the amount of light reflected off the reaction spot differs from the light reflected off of other portions of the reagent pad 129 containing no such reaction spot. This reflected light is picked up by the optical assembly, first through the lens 137 (FIG. 7), and eventually is incident upon an optical detector element 142 (FIG. 9).


The optical detector element 142 generally comprises one or more detector elements. According to one alternative construction, the detector element 142 comprises a plurality of detector elements formed in an array. The array can take any suitable configuration, and can be a linear array or an area array according to one nonlimiting example. The detector elements can comprise any suitable construction. For example, the detector elements 142 can comprise a photo diode, CCD, or CMOS based detector element. The signals transmitted to the detector element 142 are passed on to suitable electronics contained within the housing 112 (see, e.g., FIG. 10) via suitable electrical connectors, such as flexible ribbons 141. The specifics of the electronics and signal interpretation being familiar to those of ordinary skill in the art. While not necessary to enable practice of the presently claimed invention, further details concerning the structure, function, and arrangement of the optical assembly 135, and the components contained therein, can be gleaned from the disclosure contained in U.S. patent application Ser. No. 14/239,122, entitled ANALYTE DETECTION DEVICES AND METHODS WITH HEMATOCRIT/VOLUME CORRECTION AND FEEDBACK CONTROL, the entire content of which is incorporated herein by reference.


Additional components of an integrated meter 100 are illustrated in FIG. 10. The view depicted in FIG. 10 is that of an integrated meter 100 with the back panel removed to reveal the above-referenced additional components. For example, as illustrated in FIG. 10, the integrated meter 100 may further include a plurality of rollers 147 which cooperate with the cartridge 131 and a motor drive 149 thereby enabling the rotation of the cartridge 131 about the hub 133, and indexing of the analysis sites 132 with the footprint 120. The integrated meter 100 may also include a catalyst device 114 comprising a pressure pump 151 which, according to certain embodiments, comprises a pump capable of producing at least a negative or vacuum pressure at the surface of the skin located over the footprint 120. The integrated meter 100 may further include appropriate electronics, as embodied in the circuit board 153 of the illustrated embodiment. Preferably, the circuit board contains conventional electronic components capable of controlling the various functions of the integrated meter 100 in the desired manner, including the pump 151. The particulars of the circuit board 153 and electronic components disposed thereon, being well-known to those of ordinary skill in the art. The integrated meter 100 may further comprise a suitable power supply 155, such as the illustrated batteries.


As evident from FIGS. 6-10, the integrated meter 100 is configured for handheld use. However, the invention is not limited to handheld devices. For example, the present invention is also directed to integrated meters that are wearable. An example of such a wearable device is illustrated in FIG. 11. The wearable integrated device 200 illustrated therein can be generally composed of a functional portion 202 and a body-attachment portion 204. The functional portion can comprise an arrangement 10 of the type described herein. The functional portion can also have one or more of the features and elements of the handheld integrated meter described above.


According to further aspects of the present invention, modified devices and techniques are provided which permit both digital body fluid sampling and analysis as well as alternate-site body fluid sampling and analysis, which may be performed at the election of the user. In the description that follows, it should be understood that the integrated meters described herein may have any of the features and/or modes of operation than that of the previously described embodiments. For example, the integrated meter that incorporate arrangements of the present invention can include features that facilitate use on digits as well as alternate sites, at the election of the user. Such features are described in U.S. patent application Ser. No. 11/510,784 entitled BODY FLUID MONITORING AND SAMPLING DEVICES AND METHODS, the entire content of which is incorporated herein by reference.


An exemplary body fluid sampling and analysis methodology or technique, which may be utilized in conjunction with any of the above-mentioned catalyst devices or integrated meters, but is not necessarily limited thereto, is described as follows.


A user loads a fresh disposable cartridge containing a plurality of skin penetration members and analysis sites into an integrated meter. The integrated meter then reads calibration data contained in or on the cartridge. This data can be read in any suitable manner. For example, a bar code may be placed on the cartridge which can be optically read by the optical assembly contained within the meter. The integrated meter then selects the proper lookup table or algorithm to calculate an aggregate glucose measurement taking into consideration the calibration data. The meter may then place itself in a ready mode waiting for a trigger to initiate sampling and testing. The user then either manually presses a button or trigger to initiate sampling and analysis, or the device verifies that it is properly positioned on the skin of the user and ready to begin the sampling and analysis procedure. Suitable sensors to accomplish this include optical, capacitive or pressure sensors. The device then initiates a catalyst which acts to facilitate the expression of body fluid. Alternatively, the catalyst is vacuum pressure which generates suction at the sampling site. Optional sensors present in the meter may be used to monitor and control the positive or negative pressure of the catalyst. After achieving a target pressure for a desired period of time, the skin penetration member (e.g., a hollow needle) is actuated and driven into the skin of the user to create a wound site. The skin penetration member comes to rest in or directly on the wound opening created at the sampling site where it obstructs the wound opening and is in the desired position for collecting a sample of body fluid expressed from the wound. The integrated meter may further include a mechanism for detecting a whether a sufficient amount of sample has been expressed. Details of such suitable detection techniques are described in detail in U.S. Pat. No. 7,052,652, entitled ANALYTE CONCENTRATION DETECTION DEVICES AND METHODS, the entire content of which is incorporated herein by reference. Once the desired amount of body fluid has been obtained, the catalyst is deactivated. A sample of body fluid is in fluid communication with a device or mechanism which creates a detectable signal upon reaction within analyte present in the sample body fluid. For example, one such suitable mechanism is an absorbent pad containing a chemical reagent which, upon reaction with the analyte produces a reaction spot which can be optically detected. An optical assembly which is in optical communication with the above described signal generating mechanism is utilized to detect the signal created via reaction with the analyte and communicate the signals to supporting electronics contained within the meter. The concentration of a target analyte (e.g., glucose) can then be calculated using these signals as a basis. Additional factors may be considered during these calculations, such as the sample size, levels of other substances contained in the sample (e.g. hematocrit), etc. Such optional calculation techniques are described in further detail in U.S. patent application Ser. No. 11/239,122, entitled ANALYTE DETECTION DEVICES AND METHODS WITH HEMATOCRIT/VOLUME CORRECTION AND FEEDBACK CONTROL, the entire content of which is incorporated herein by reference. These calculations quantify the amount of analyte contained in the sample body fluid. This quantity is displayed on a suitable display contained within the meter which can be easily read by the user. The integrated meter then automatically may retract the skin-penetration member and indexes the disposable cartridge to present a fresh unused skin penetration member which will be utilized to perform the next sampling and analysis event.


EXAMPLE

A prototype was constructed using a torsional spring actuator and a needle designed to position the needle on or in the wound (i.e., to obstruct the wound opening). A vacuum catalyst was also utilized. Results of an evaluation of this prototype are summarized in the following table.

















Population












Camino Medical
Camino Medical











Experiment Name












PAMF1
PAMF2







Actuator
Beam
Torsional



Actuator Version
2.1
5.0 (w/dwell)



# of Subjects
21
19



Probability BV > 250 nl
94%
93%



Probability BV > 300 nl
90%
91%



Probability BV > 350 nl
85%
85%



Average BV (nl)
985
1137










The table shows two experiments for which the lancet design, footprint design and footprint contact force were identical. Experiment PAMF1 used a cantilevered beam actuator; this actuator did not allow the needle to remain in or on the wound. Experiment PAMF2 used a torsional coil actuator, this actuator caused the needle to dwell the needle in or on the skin. Surprisingly, the performance of the torsional coil was comparable in blood volume (BV) probabilities to the cantilevered beam. Even more surprising was the observation that the torsional coil actually produced a slightly higher average blood volume.


Numbers expressing quantities of ingredients, constituents, reaction conditions, and so forth used in this specification are to be understood as being modified in all instances by the term “about”. Notwithstanding that the numerical ranges and parameters setting forth, the broad scope of the subject matter presented herein are approximations, the numerical values set forth are indicated as precisely as possible. Any numerical value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective measurement techniques. None of the elements recited in the appended claims should be interpreted as invoking 35 U.S.C. § 112, ¶6, unless the term “means” is explicitly used.


Although the present invention has been described in connection with preferred embodiments thereof, it will be appreciated by those skilled in the art that additions, deletions, modifications, and substitutions not specifically described may be made without departing from the spirit and scope of the invention as defined in the appended claims.

Claims
  • 1. An arrangement for producing a sample of body fluid from a wound opening created in a skin surface, the arrangement comprising: a skin penetration member having a first end configured to pierce the skin surface, and a lumen in fluid communication with the first end;a spring actuator configured to drive the skin penetration member to form the wound opening, wherein the spring actuator has a neutral rest position and is configured to allow the skin penetration member to obstruct the wound opening when the spring actuator is in the neutral rest position;a needle hub connecting the skin penetration member and the spring actuator; anda compartment at least partially enclosing the skin penetration member, the spring actuator, and the needle hub.
  • 2. The arrangement of claim 1, further comprising a cartridge comprising a plurality of compartments and a plurality of skin penetration members, each compartment of the plurality of compartments at least partially enclosing a respective skin penetration member of the plurality of skin penetration members.
  • 3. The arrangement of claim 1, wherein the spring actuator drives the skin penetration member in an arcuate path.
  • 4. The arrangement of claim 1, further comprising at least one catalyst device configured to apply vacuum, positive pressure, or heat to the skin surface.
  • 5. The arrangement of claim 4, wherein the at least one catalyst device comprises a pump, and wherein the pump is configured and arranged to apply vacuum to the skin surfaces.
  • 6. The arrangement of claim 1, further comprising a housing, and wherein a footprint is disposed on the housing and is configured to be applied to the skin surface.
  • 7. The arrangement of claim 6, wherein the footprint has an opening, and wherein the opening has a diameter of 3-8 mm.
  • 8. The arrangement of claim 6, wherein the footprint comprises an elastomeric seal.
  • 9. The arrangement of claim 6, wherein the housing comprises at least one sensor configured to detect application of the footprint to the skin surface.
  • 10. The arrangement of claim 1, wherein the skin penetration member comprises a microneedle.
  • 11. An arrangement for producing a sample of body fluid from a wound opening created in a skin surface, the arrangement comprising: a skin penetration member having a first end configured to pierce the skin surface, and a lumen in fluid communication with the first end; anda torsional spring actuator configured to drive the skin penetration member in an arcuate path to form the wound opening, wherein the torsional spring actuator has a neutral rest position and is constructed and positioned such that the skin penetration member obstructs the wound opening when the torsional spring actuator is in the neutral rest position.
  • 12. The arrangement of claim 11, further comprising a cartridge comprising a plurality of compartments and a plurality of skin penetration members, each compartment of the plurality of compartments at least partially enclosing a respective skin penetration member of the plurality of skin penetration members.
  • 13. The arrangement of claim 11, wherein the torsional spring actuator drives the skin penetration member in an arcuate path.
  • 14. The arrangement of claim 11, further comprising at least one catalyst device configured to apply vacuum, positive pressure, or heat to the skin surface.
  • 15. The arrangement of claim 14, wherein the at least one catalyst device comprises a pump, and wherein the pump is configured and arranged to apply vacuum to the skin surface.
  • 16. The arrangement of claim 11, further comprising a housing, and wherein a footprint is disposed on the housing and is configured to be applied to the skin surface.
  • 17. The arrangement of claim 16, wherein the footprint has an opening, and wherein the opening has a diameter of 3-8 mm.
  • 18. The arrangement of claim 16, wherein the footprint comprises an elastomeric seal.
  • 19. The arrangement of claim 16, wherein the housing comprises at least one sensor configured to detect application of the footprint to the skin surface.
  • 20. The arrangement of claim 11, wherein the skin penetration member comprises a microneedle.
Parent Case Info

The present application is a continuation of and claims priority to U.S. patent application Ser. No. 14/743,867, filed Jun. 18, 2015, which issued as U.S. Pat. No. 9,839,384 on Dec. 12, 2017, which is a continuation of and claims priority to U.S. patent application Ser. No. 14/446,262, filed Jul. 29, 2014, which issued as U.S. Pat. No. 9,060,723 on Jun. 23, 2015, which is a continuation of and claims priority to U.S. patent application Ser. No. 13/752,261, filed Jan. 28, 2013, which issued as U.S. Pat. No. 8,795,201 on Aug. 5, 2014, which is a continuation of and claims priority to U.S. patent application Ser. No. 13/197,592, filed Aug. 3, 2011, which issued as U.S. Pat. No. 8,360,993 on Jan. 29, 2013, which is a continuation of and claims priority to U.S. patent application Ser. No. 11/941,403, filed Nov. 16, 2007, which issued as U.S. Pat. No. 8,012,104 on Sep. 6, 2011, which is a divisional of and claims priority to, U.S. patent application Ser. No. 11/529,613, filed Sep. 29, 2006, which issued as U.S. Pat. No. 8,012,103 on Sep. 6, 2011, which claims priority pursuant to 35 U.S.C. § 119 to U.S. Patent Application No. 60/721,966, filed Sep. 30, 2005, the entire contents of each of which are hereby incorporated herein by reference in this application.

US Referenced Citations (756)
Number Name Date Kind
842690 Oswalt Jan 1907 A
D137874 Partridge May 1944 S
2749797 Harks Mar 1950 A
3092465 Adams, Jr. Jun 1963 A
3310002 Wilburn Mar 1967 A
3620209 Kravitz Nov 1971 A
3623475 Sanz et al. Nov 1971 A
3626929 Sanz et al. Dec 1971 A
3630957 Rey Dec 1971 A
D223165 Komendat Mar 1972 S
3723064 Liotta Mar 1973 A
3741197 Sanz et al. Jun 1973 A
3961898 Neeley et al. Jun 1976 A
3992158 Przybylowicz et al. Nov 1976 A
4014328 Cluff et al. Mar 1977 A
4042335 Clement Aug 1977 A
4057394 Genshaw Nov 1977 A
4109655 Chacornac Aug 1978 A
4253083 Imamura Feb 1981 A
4254083 Columbus Mar 1981 A
4258001 Pierce et al. Mar 1981 A
4260257 Neeley et al. Apr 1981 A
4289459 Neeley et al. Sep 1981 A
4321397 Nix et al. Mar 1982 A
4350762 DeLuca et al. Sep 1982 A
4394512 Batz Jul 1983 A
4414975 Ryder et al. Nov 1983 A
4416279 Lindner et al. Nov 1983 A
4418037 Katsuyama et al. Nov 1983 A
4422941 Vaughan, Jr. et al. Dec 1983 A
4429700 Thees et al. Feb 1984 A
4627445 Garcia et al. Dec 1986 A
4637403 Garcia et al. Jan 1987 A
4637406 Guinn et al. Jan 1987 A
4653513 Dombrowski Mar 1987 A
4661319 Lape Apr 1987 A
4702261 Cornell et al. Oct 1987 A
4711250 Gilbaugh, Jr. et al. Dec 1987 A
4737458 Batz et al. Apr 1988 A
4747687 Hoppe et al. May 1988 A
4767415 Duffy Aug 1988 A
4774192 Terminiello et al. Sep 1988 A
4787398 Garcia et al. Nov 1988 A
4790979 Terminiello et al. Dec 1988 A
4794926 Munsch et al. Jan 1989 A
4815843 Tiefenthaler et al. Mar 1989 A
4829470 Wang May 1989 A
4844095 Chiodo et al. Jul 1989 A
4846785 Cassou et al. Jul 1989 A
4887306 Hwang et al. Dec 1989 A
4920977 Haynes May 1990 A
4929426 Bodai et al. May 1990 A
4930525 Palestrant Jun 1990 A
4935346 Phillips Jun 1990 A
4953552 De Marzo Sep 1990 A
4966646 Zdeblick Oct 1990 A
4983178 Schnell Jan 1991 A
4995402 Smith Feb 1991 A
5029583 Meserol Jul 1991 A
5035704 Lambert et al. Jul 1991 A
5037199 Hlousek Aug 1991 A
5049487 Phillips et al. Sep 1991 A
5050617 Columbus et al. Sep 1991 A
5054878 Gergely et al. Oct 1991 A
5059394 Phillips et al. Oct 1991 A
5077199 Basagni et al. Dec 1991 A
5094943 Siedel et al. Mar 1992 A
5110724 Hewett May 1992 A
5114350 Hewett May 1992 A
5116759 Klainer et al. May 1992 A
5131404 Neeley et al. Jul 1992 A
5141868 Shanks et al. Aug 1992 A
5145565 Kater et al. Sep 1992 A
5146437 Boucheron Sep 1992 A
5153416 Neeley Oct 1992 A
5164575 Neeley et al. Nov 1992 A
5166498 Neeley Nov 1992 A
5174291 Schoonen et al. Dec 1992 A
5176632 Bernardi Jan 1993 A
5179005 Phillips et al. Jan 1993 A
5183741 Arai et al. Feb 1993 A
5194393 Hugl et al. Mar 1993 A
5196302 Kidwell Mar 1993 A
5208163 Charlton et al. May 1993 A
5213966 Vuorinen et al. May 1993 A
5217480 Habar et al. Jun 1993 A
5218966 Yamasawa Jun 1993 A
5223219 Subramanian et al. Jun 1993 A
5228972 Osaka et al. Jul 1993 A
5234818 Zimmermann et al. Aug 1993 A
5241969 Carson et al. Sep 1993 A
5251126 Kahn et al. Oct 1993 A
D341848 Bigelow et al. Nov 1993 S
5269800 Davis, Jr. Dec 1993 A
5275159 Griebel Jan 1994 A
5278079 Gubinski et al. Jan 1994 A
5288646 Lundsgaard et al. Feb 1994 A
5299571 Mastrototaro Apr 1994 A
5301686 Newman Apr 1994 A
5302513 Mike et al. Apr 1994 A
5304468 Phillips et al. Apr 1994 A
5306623 Kiser et al. Apr 1994 A
5308767 Terashima May 1994 A
5314441 Cusack et al. May 1994 A
5320607 Ishibashi Jun 1994 A
5354537 Moreno Oct 1994 A
5360595 Bell et al. Nov 1994 A
5368047 Suzuki et al. Nov 1994 A
5383512 Jarvis Jan 1995 A
5390671 Lord et al. Feb 1995 A
5395388 Schraga Mar 1995 A
5399316 Yamada Mar 1995 A
5401110 Neeley Mar 1995 A
5402798 Swierczek et al. Apr 1995 A
5426032 Phillips et al. Jun 1995 A
5441513 Roth Aug 1995 A
5451350 Macho et al. Sep 1995 A
5458140 Eppstein et al. Oct 1995 A
5460777 Kitajima et al. Oct 1995 A
5460968 Yoshida et al. Oct 1995 A
5482473 Lord et al. Jan 1996 A
5489414 Schreiber et al. Feb 1996 A
5506200 Hirschkoff et al. Apr 1996 A
5507288 Böcker et al. Apr 1996 A
5508200 Tiffany et al. Apr 1996 A
5510266 Bonner et al. Apr 1996 A
5514152 Smith May 1996 A
5518689 Dosmann et al. May 1996 A
5525518 Lundsgaard et al. Jun 1996 A
5527892 Borsotti et al. Jun 1996 A
5563042 Phillips et al. Oct 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569287 Tezuka et al. Oct 1996 A
5575403 Charlton et al. Nov 1996 A
5577499 Teves Nov 1996 A
5582184 Erickson et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5591139 Lin et al. Jan 1997 A
5593838 Zanzucchi et al. Jan 1997 A
5602647 Xu et al. Feb 1997 A
5611809 Marshall et al. Mar 1997 A
5611999 Dosmann et al. Mar 1997 A
5624458 Lipscher Apr 1997 A
5630986 Charlton et al. May 1997 A
5632410 Moulton et al. May 1997 A
5636632 Bommannan et al. Jun 1997 A
5638828 Lauks et al. Jun 1997 A
5647851 Pokras Jul 1997 A
5658515 Lee et al. Aug 1997 A
5660791 Brenneman Aug 1997 A
5670031 Hintsche et al. Sep 1997 A
5676850 Reed et al. Oct 1997 A
5680858 Hansen et al. Oct 1997 A
5681484 Zanzucchi et al. Oct 1997 A
5682233 Brinda Oct 1997 A
5697901 Eriksson Dec 1997 A
5700695 Yassinzadeh et al. Dec 1997 A
5701181 Boiarski et al. Dec 1997 A
5701910 Powles et al. Dec 1997 A
D389761 Thomas Jan 1998 S
5705018 Hartley Jan 1998 A
5708247 McAleer Jan 1998 A
5708787 Nakano et al. Jan 1998 A
5715417 Gardien et al. Feb 1998 A
5730753 Morita Mar 1998 A
5735273 Kurnik et al. Apr 1998 A
5736103 Pugh Apr 1998 A
5741211 Renirie et al. Apr 1998 A
5746217 Erickson et al. May 1998 A
5746720 Stouder, Jr. May 1998 A
5753452 Smith May 1998 A
5757666 Schreiber et al. May 1998 A
5759364 Charlton et al. Jun 1998 A
5766066 Ranniger Jun 1998 A
5771890 Tamada Jun 1998 A
5789255 Yu Aug 1998 A
5797693 Jaeger Aug 1998 A
5800420 Gross et al. Sep 1998 A
5801057 Smart et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5820570 Erickson et al. Oct 1998 A
5827183 Kurnik et al. Oct 1998 A
5840020 Heinonen et al. Nov 1998 A
5841126 Fossum et al. Nov 1998 A
5843692 Phillips et al. Dec 1998 A
5846837 Thym et al. Dec 1998 A
5851215 Mawhirt et al. Dec 1998 A
5854074 Charlton et al. Dec 1998 A
D403975 Douglas et al. Jan 1999 S
5855801 Lin et al. Jan 1999 A
5856195 Charlton et al. Jan 1999 A
5858194 Bell Jan 1999 A
5866281 Guckel et al. Feb 1999 A
5866349 Lilja et al. Feb 1999 A
5871494 Simons et al. Feb 1999 A
5879310 Sopp et al. Mar 1999 A
5879326 Godshall et al. Mar 1999 A
5879367 Latterell et al. Mar 1999 A
5885839 Lingane et al. Mar 1999 A
5891053 Sesekura Apr 1999 A
5893870 Talen et al. Apr 1999 A
D411621 Eisenbarth et al. Jun 1999 S
5911711 Pelkey Jun 1999 A
5911737 Lee et al. Jun 1999 A
5912139 Iwata et al. Jun 1999 A
5925021 Castellano et al. Jul 1999 A
5926271 Couderc et al. Jul 1999 A
5928207 Pisano et al. Jul 1999 A
5930873 Wyser Aug 1999 A
5938679 Freeman et al. Aug 1999 A
5945678 Yanagisawa Aug 1999 A
5951492 Douglas et al. Sep 1999 A
5951493 Douglas et al. Sep 1999 A
5951521 Mastrototaro et al. Sep 1999 A
5954685 Tierney Sep 1999 A
5962215 Douglas et al. Oct 1999 A
5968760 Phillips et al. Oct 1999 A
5968765 Grage et al. Oct 1999 A
5968836 Matzinger et al. Oct 1999 A
5971941 Simons et al. Oct 1999 A
5972294 Smith et al. Oct 1999 A
5986754 Harding Nov 1999 A
5989409 Kurnik et al. Nov 1999 A
5993189 Mueller et al. Nov 1999 A
D417504 Love et al. Dec 1999 S
6001067 Shults et al. Dec 1999 A
6005545 Nishida et al. Dec 1999 A
6010463 Lauks et al. Jan 2000 A
6010519 Mawhirt et al. Jan 2000 A
6014135 Fernandes Jan 2000 A
6014577 Henning et al. Jan 2000 A
6015969 Nathel et al. Jan 2000 A
6023629 Tamada Feb 2000 A
6027459 Shain et al. Feb 2000 A
6030827 Davis et al. Feb 2000 A
6032059 Henning et al. Feb 2000 A
6036924 Simons et al. Mar 2000 A
6037141 Banes Mar 2000 A
6041253 Kost et al. Mar 2000 A
6045753 Loewy et al. Apr 2000 A
6048352 Douglas et al. Apr 2000 A
6050988 Zuck Apr 2000 A
6056701 Duchon et al. May 2000 A
6056734 Jacobsen et al. May 2000 A
6058321 Swayze et al. May 2000 A
6059815 Lee et al. May 2000 A
6061128 Zweig et al. May 2000 A
6063039 Cunningham et al. May 2000 A
6071251 Cunningham et al. Jun 2000 A
6071294 Simons et al. Jun 2000 A
6077660 Wong et al. Jun 2000 A
6080116 Erickson et al. Jun 2000 A
6083196 Trautman et al. Jul 2000 A
6086544 Hibner et al. Jul 2000 A
6090790 Eriksson Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6093156 Cunningham et al. Jul 2000 A
6097831 Wieck et al. Aug 2000 A
6099484 Douglas et al. Aug 2000 A
6100107 Lei et al. Aug 2000 A
6102933 Lee et al. Aug 2000 A
6103033 Say et al. Aug 2000 A
6103197 Werner Aug 2000 A
6106751 Talbot et al. Aug 2000 A
6118126 Zanzucchi Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121050 Han Sep 2000 A
6123861 Santini, Jr. et al. Sep 2000 A
6126899 Woudenberg et al. Oct 2000 A
6132449 Lum et al. Oct 2000 A
6139562 Mauze et al. Oct 2000 A
6142939 Eppstein et al. Nov 2000 A
6152942 Brenneman et al. Nov 2000 A
6162639 Douglas Dec 2000 A
6172743 Kley et al. Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6176865 Mauze et al. Jan 2001 B1
6183434 Eppstein et al. Feb 2001 B1
6183489 Douglas et al. Feb 2001 B1
6184990 Amirkhanian et al. Feb 2001 B1
6187210 Lebouiz et al. Feb 2001 B1
6192891 Gravel et al. Feb 2001 B1
6193873 Ohara et al. Feb 2001 B1
6197257 Raskas Mar 2001 B1
6200296 Dibiasi et al. Mar 2001 B1
6206841 Cunningham et al. Mar 2001 B1
6214626 Meller et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6228100 Schraga May 2001 B1
6230051 Cormier et al. May 2001 B1
6231531 Lum et al. May 2001 B1
6241862 McAleer et al. Jun 2001 B1
6242207 Douglas et al. Jun 2001 B1
6245215 Douglas et al. Jun 2001 B1
6246966 Perry Jun 2001 B1
6251083 Yum et al. Jun 2001 B1
6251260 Heller et al. Jun 2001 B1
6254586 Mann et al. Jul 2001 B1
6255061 Mori et al. Jul 2001 B1
6256533 Yuzhakov et al. Jul 2001 B1
6268162 Phillips et al. Jul 2001 B1
6271045 Douglas et al. Aug 2001 B1
6272364 Kurnik Aug 2001 B1
6283926 Cunningham et al. Sep 2001 B1
6289230 Chaiken et al. Sep 2001 B1
6298254 Tamada Oct 2001 B2
6299578 Kurnik et al. Oct 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309351 Kurnik et al. Oct 2001 B1
D450711 Istvan et al. Nov 2001 S
6312612 Sherman et al. Nov 2001 B1
6312888 Wong et al. Nov 2001 B1
6315738 Nishikawa et al. Nov 2001 B1
6322808 Trautman et al. Nov 2001 B1
6329161 Heller et al. Dec 2001 B1
6331266 Powell et al. Dec 2001 B1
6332871 Douglas et al. Dec 2001 B1
6334856 Allen et al. Jan 2002 B1
6350273 Minagawa et al. Feb 2002 B1
6352514 Douglas et al. Mar 2002 B1
6356776 Berner et al. Mar 2002 B1
6358265 Thorne, Jr. et al. Mar 2002 B1
6364890 Lum et al. Apr 2002 B1
6375626 Allen et al. Apr 2002 B1
6375627 Mauze et al. Apr 2002 B1
6379969 Mauze et al. Apr 2002 B1
6391005 Lum et al. May 2002 B1
6391645 Huang et al. May 2002 B1
6402704 McMorrow Jun 2002 B1
6409679 Pyo Jun 2002 B2
6428664 BhulLar et al. Aug 2002 B1
6449608 Morita et al. Sep 2002 B1
6455324 Douglas Sep 2002 B1
6493069 Nagashimada et al. Dec 2002 B1
6500134 Cassone Dec 2002 B1
6520973 McGarry Feb 2003 B1
6530892 Kelly Mar 2003 B1
6537243 Henning et al. Mar 2003 B1
6540675 Aceti et al. Apr 2003 B2
6544193 Abreu Apr 2003 B2
6544475 Douglas et al. Apr 2003 B1
6549796 Sohrab Apr 2003 B2
6555061 Leong et al. Apr 2003 B1
6558624 Lemmon et al. May 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6589260 Schmelzeisen-Redeker et al. Jul 2003 B1
6591124 Sherman et al. Jul 2003 B2
6591125 Buse et al. Jul 2003 B1
6602205 Erickson et al. Aug 2003 B1
6612111 Hodges et al. Sep 2003 B1
6616616 Fritz et al. Sep 2003 B2
6626874 Duchamp Sep 2003 B1
6656167 Numao et al. Dec 2003 B2
6662031 Khalil et al. Dec 2003 B1
6679852 Schmelzeisen-Redeker et al. Jan 2004 B1
6690467 Reel Feb 2004 B1
6706000 Perez et al. Mar 2004 B2
6706049 Moerman Mar 2004 B2
6706159 Moerman et al. Mar 2004 B2
6740800 Cunningham May 2004 B1
6744502 Hoff et al. Jun 2004 B2
6748275 Lattner et al. Jun 2004 B2
6753187 Cizdziel et al. Jun 2004 B2
6766817 da Silva Jul 2004 B2
6775001 Friberg et al. Aug 2004 B2
6793633 Douglas et al. Sep 2004 B2
6830669 Miyazaki et al. Dec 2004 B2
6836678 Tu Dec 2004 B2
6837858 Cunningham et al. Jan 2005 B2
6847451 Pugh Jan 2005 B2
6849052 Uchigaki et al. Feb 2005 B2
6890421 Ohara et al. May 2005 B2
6896850 Subramanian et al. May 2005 B2
6903815 Uchiyama et al. Jun 2005 B2
6918404 Dias Da Silva Jul 2005 B2
6919960 Hansen et al. Jul 2005 B2
6923764 Aceti et al. Aug 2005 B2
6936476 Anderson et al. Aug 2005 B1
D511214 Sasano et al. Nov 2005 S
6988996 Roe et al. Jan 2006 B2
7004928 Aceti et al. Feb 2006 B2
7011630 Desai et al. Mar 2006 B2
7025774 Freeman et al. Apr 2006 B2
D519868 Sasano et al. May 2006 S
7052652 Zanzucchi et al. May 2006 B2
7066586 Da Silva Jun 2006 B2
7066890 Lam et al. Jun 2006 B1
7141058 Briggs et al. Nov 2006 B2
7154592 Reynolds et al. Dec 2006 B2
7156809 Quy Jan 2007 B2
7163616 Vreeke et al. Jan 2007 B2
7183552 Russell Feb 2007 B2
7192061 Martin Mar 2007 B2
D540343 Cummins Apr 2007 S
7223365 Von Der Goltz May 2007 B2
7225008 Ward et al. May 2007 B1
7226461 Boecker et al. Jun 2007 B2
7229458 Boecker et al. Jun 2007 B2
7258673 Racchini et al. Aug 2007 B2
D551243 Young Sep 2007 S
7270970 Anderson et al. Sep 2007 B2
7297151 Boecker et al. Nov 2007 B2
7299081 Mace et al. Nov 2007 B2
7316700 Alden et al. Jan 2008 B2
7323141 Kirchhevel et al. Jan 2008 B2
7323315 Marfurt Jan 2008 B2
7341830 Horn et al. Mar 2008 B2
7343188 Sohrab Mar 2008 B2
7344507 Briggs et al. Mar 2008 B2
7377904 Conway et al. May 2008 B2
7379167 Mawhirt et al. May 2008 B2
7427377 Zanzucchi et al. Sep 2008 B2
7439033 Marfurt Oct 2008 B2
D580068 Shigesada et al. Nov 2008 S
D580558 Shigesada et al. Nov 2008 S
7501053 Karinka et al. Mar 2009 B2
7537571 Freeman et al. May 2009 B2
D599373 Kobayashi et al. Sep 2009 S
D601257 Berlninger et al. Sep 2009 S
7582063 Wurster et al. Sep 2009 B2
7585278 Aceti et al. Sep 2009 B2
D601444 Jones et al. Oct 2009 S
D601578 Poulet et al. Oct 2009 S
7655019 LeVaughn et al. Feb 2010 B2
7682318 Alden et al. Mar 2010 B2
7713214 Freeman et al. May 2010 B2
7725149 Peyser et al. May 2010 B2
D622393 Gatrall et al. Aug 2010 S
7780631 Lum et al. Aug 2010 B2
7803123 Perez et al. Sep 2010 B2
7819822 Calasso et al. Oct 2010 B2
7841992 Freeman et al. Nov 2010 B2
7879058 Ikeda Feb 2011 B2
7883473 LeVaughn et al. Feb 2011 B2
7887494 Emery et al. Feb 2011 B2
7955492 Fujiwara et al. Jun 2011 B2
7964372 Marfurt Jun 2011 B2
D642191 Barnett et al. Jul 2011 S
7972861 Deng et al. Jul 2011 B2
7988644 Freeman et al. Aug 2011 B2
8012103 Escutia et al. Sep 2011 B2
8012104 Escutia et al. Sep 2011 B2
8105849 McDevitt et al. Jan 2012 B2
D654926 Lipman et al. Feb 2012 S
8173439 Petrich et al. May 2012 B2
8184273 Dosmann et al. May 2012 B2
8202231 Freeman et al. Jun 2012 B2
8231832 Zanzucchi et al. Jul 2012 B2
8251920 Vreeke et al. Aug 2012 B2
8262614 Freeman et al. Sep 2012 B2
8267870 Freeman et al. Sep 2012 B2
8280476 Jina Oct 2012 B2
8298255 Conway et al. Oct 2012 B2
8303518 Aceti et al. Nov 2012 B2
8360993 Escutia et al. Jan 2013 B2
8360994 Escutia et al. Jan 2013 B2
8372015 Escutia et al. Feb 2013 B2
8372016 Freeman et al. Feb 2013 B2
8376959 Deck Feb 2013 B2
8382681 Escutia et al. Feb 2013 B2
8391940 Matzinger et al. Mar 2013 B2
8419657 Roe Apr 2013 B2
D691174 Lipman et al. Oct 2013 S
8574168 Freeman et al. Nov 2013 B2
8574895 Freeman et al. Nov 2013 B2
8696880 Beer et al. Apr 2014 B2
8702624 Alden Apr 2014 B2
8795201 Escutia et al. Aug 2014 B2
8801631 Escutia et al. Aug 2014 B2
8919605 Lipman et al. Dec 2014 B2
8969097 Emery et al. Mar 2015 B2
9017356 Schraga et al. Apr 2015 B2
9034639 Freeman et al. May 2015 B2
9060723 Escutia et al. Jun 2015 B2
9060727 Saikley et al. Jun 2015 B2
9063102 Hoenes et al. Jun 2015 B2
9089678 Freeman et al. Jul 2015 B2
9095292 Zanzucchi et al. Aug 2015 B2
9095847 Porsch et al. Aug 2015 B2
9097679 List et al. Aug 2015 B2
9101302 Mace et al. Aug 2015 B2
9131886 Harttig et al. Sep 2015 B2
9138179 Hoenes et al. Sep 2015 B2
9149215 Werner et al. Oct 2015 B2
9173608 Kuhr et al. Nov 2015 B2
9179872 Roe et al. Nov 2015 B2
9186097 Frey et al. Nov 2015 B2
9186104 Kraemer et al. Nov 2015 B2
9186468 Freeman et al. Nov 2015 B2
9226704 Deck Jan 2016 B2
9301171 List et al. Apr 2016 B2
9314194 Deshmukh et al. Apr 2016 B2
9326718 Petrich et al. May 2016 B2
9332931 Chan May 2016 B2
9332932 Okuyama et al. May 2016 B2
9339612 Freeman et al. May 2016 B2
9351680 Boecker et al. May 2016 B2
9364172 Konya et al. Jun 2016 B2
9366636 Emery et al. Jun 2016 B2
9375169 Choi et al. Jun 2016 B2
9375177 Planman et al. Jun 2016 B2
9380963 Gofman et al. Jul 2016 B2
9380974 Litherland et al. Jul 2016 B2
9386944 Freeman et al. Jul 2016 B2
9392968 Schraga Jul 2016 B2
9439591 Frey et al. Sep 2016 B2
9463463 He et al. Oct 2016 B2
9480419 Weiss et al. Nov 2016 B2
9480420 Konya et al. Nov 2016 B2
9486164 Roe Nov 2016 B2
9488585 Emeric et al. Nov 2016 B2
9517027 Kan et al. Dec 2016 B2
9560993 Freeman Feb 2017 B2
9561000 Lum Feb 2017 B2
9573761 List Feb 2017 B2
9599552 Baldus et al. Mar 2017 B2
9668687 Volkmuth et al. Jun 2017 B2
9671387 Thoes et al. Jun 2017 B2
9717452 Roe et al. Aug 2017 B2
9724021 Freeman et al. Aug 2017 B2
9730625 Krasnow et al. Aug 2017 B2
9795334 Freeman et al. Oct 2017 B2
9820684 Freeman et al. Nov 2017 B2
9833183 Escutia et al. Dec 2017 B2
9839384 Escutia et al. Dec 2017 B2
9877676 Konya et al. Jan 2018 B2
9880254 Richter et al. Jan 2018 B2
9883828 Haar et al. Feb 2018 B2
9897610 Lipman et al. Feb 2018 B2
9927386 Wang et al. Mar 2018 B2
9931478 Hirshberg et al. Apr 2018 B2
9939403 Richter et al. Apr 2018 B2
9939404 Richter et al. Apr 2018 B2
9943256 Varsaysky et al. Apr 2018 B2
9943259 Kuhr et al. Apr 2018 B2
9949679 Renlund Apr 2018 B2
9965587 Aykroyd et al. May 2018 B2
9968284 Vidalis et al. May 2018 B2
9974471 Kam et al. May 2018 B1
9983140 Dickopf May 2018 B2
9987427 Polsky et al. Jun 2018 B1
10034628 Freeman et al. Jul 2018 B2
10080517 Chen et al. Sep 2018 B2
10194838 Weiss et al. Feb 2019 B2
10226208 Emery et al. Mar 2019 B2
10278621 List May 2019 B2
10309905 Dickopf Jun 2019 B2
10327689 Krasnow et al. Jun 2019 B2
10330667 Lipman et al. Jun 2019 B2
10383556 Lipman et al. Aug 2019 B2
10429337 Malecha et al. Oct 2019 B2
10433780 Escutia et al. Oct 2019 B2
10441205 Litherland Oct 2019 B2
20010001034 Douglas May 2001 A1
20010027277 Klitmose Oct 2001 A1
20010027328 Lum et al. Oct 2001 A1
20010053891 Ackley Dec 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020002344 Douglas et al. Jan 2002 A1
20020004640 Conn et al. Jan 2002 A1
20020006355 Whitson Jan 2002 A1
20020016568 Lebel et al. Feb 2002 A1
20020020688 Sherman et al. Feb 2002 A1
20020022934 Vogel et al. Feb 2002 A1
20020023852 Mcivor et al. Feb 2002 A1
20020042594 Lum et al. Apr 2002 A1
20020045241 Laska et al. Apr 2002 A1
20020052618 Haar et al. May 2002 A1
20020067481 Wolf et al. Jun 2002 A1
20020087056 Aceti et al. Jul 2002 A1
20020136667 Subramanian et al. Sep 2002 A1
20020137998 Smart et al. Sep 2002 A1
20020160520 Orloff et al. Oct 2002 A1
20020168290 Yuzhakov et al. Nov 2002 A1
20020169394 Eppstein et al. Nov 2002 A1
20020169411 Sherman et al. Nov 2002 A1
20020177761 Orloff et al. Nov 2002 A1
20020177764 Sohrab Nov 2002 A1
20020183102 Withers et al. Dec 2002 A1
20020188223 Perez et al. Dec 2002 A1
20020198444 Uchigaki et al. Dec 2002 A1
20030012693 Otillar et al. Jan 2003 A1
20030028087 Yuzhakov et al. Feb 2003 A1
20030028125 Yuzhakov et al. Feb 2003 A1
20030039587 Niermann Feb 2003 A1
20030060730 Perez Mar 2003 A1
20030083685 Freeman et al. May 2003 A1
20030083686 Freeman et al. May 2003 A1
20030105961 Zatloukal et al. Jun 2003 A1
20030116596 Terasawa Jun 2003 A1
20030135166 Gonnelli Jul 2003 A1
20030135333 Aceti Jul 2003 A1
20030143746 Sage Jul 2003 A1
20030153844 Smith et al. Aug 2003 A1
20030153900 Aceti Aug 2003 A1
20030175987 Verdonk et al. Sep 2003 A1
20030187395 Gabel et al. Oct 2003 A1
20030206302 Pugh Nov 2003 A1
20030207441 Eyster et al. Nov 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030211619 Olson et al. Nov 2003 A1
20030212344 Yuzhakov et al. Nov 2003 A1
20030212345 McAllister et al. Nov 2003 A1
20030212347 Sohrab Nov 2003 A1
20030216628 Bortz et al. Nov 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040030353 Schmelzeisen-Redeker et al. Feb 2004 A1
20040039303 Wurster et al. Feb 2004 A1
20040049219 Briggs et al. Mar 2004 A1
20040059256 Perez Mar 2004 A1
20040072357 Stiene et al. Apr 2004 A1
20040073140 Douglas Apr 2004 A1
20040092842 Boecker et al. May 2004 A1
20040092995 Boecker et al. May 2004 A1
20040094432 Neel et al. May 2004 A1
20040096959 Stiene et al. May 2004 A1
20040097796 Berman et al. May 2004 A1
20040098009 Boecker et al. May 2004 A1
20040102803 Boecker et al. May 2004 A1
20040120848 Teodorczyk Jun 2004 A1
20040122339 Roe et al. Jun 2004 A1
20040132167 Rule et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040155084 Brown Aug 2004 A1
20040157339 Burke et al. Aug 2004 A1
20040178218 Schomakers et al. Sep 2004 A1
20040186394 Roe et al. Sep 2004 A1
20040191119 Zanzucchi et al. Sep 2004 A1
20040202576 Aceti et al. Oct 2004 A1
20040230216 Levaughn et al. Nov 2004 A1
20040236251 Roe et al. Nov 2004 A1
20040238675 Banaszkiewicz et al. Dec 2004 A1
20040242982 Sakata et al. Dec 2004 A1
20040249253 Racchini et al. Dec 2004 A1
20040259180 Burke et al. Dec 2004 A1
20050004494 Perez et al. Jan 2005 A1
20050010134 Douglas et al. Jan 2005 A1
20050015020 LeVaughn et al. Jan 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050033340 Lipoma et al. Feb 2005 A1
20050038680 McMahon Feb 2005 A1
20050070819 Poux et al. Mar 2005 A1
20050096686 Allen May 2005 A1
20050106713 Phan et al. May 2005 A1
20050109386 Marshall May 2005 A1
20050153428 Matsumoto Jul 2005 A1
20050154410 Conway et al. Jul 2005 A1
20050159678 Taniike et al. Jul 2005 A1
20050176133 Miyashita et al. Aug 2005 A1
20050187532 Thurau et al. Aug 2005 A1
20050192492 Cho et al. Sep 2005 A1
20050202567 Zanzucchi et al. Sep 2005 A1
20050202733 Yoshimura et al. Sep 2005 A1
20050209518 Sage, Jr. et al. Sep 2005 A1
20050215872 Berner et al. Sep 2005 A1
20050215923 Wiegel Sep 2005 A1
20050234494 Conway et al. Oct 2005 A1
20050245844 Mace et al. Nov 2005 A1
20050255001 Padmaabhan et al. Nov 2005 A1
20050277972 Wong et al. Dec 2005 A1
20060008389 Sacherer et al. Jan 2006 A1
20060036134 Tarassenko et al. Feb 2006 A1
20060052724 Roe Mar 2006 A1
20060064035 Wang et al. Mar 2006 A1
20060079809 Goldberger et al. Apr 2006 A1
20060094985 Aceti et al. May 2006 A1
20060117616 Jones et al. Jun 2006 A1
20060122536 Haar et al. Jun 2006 A1
20060135873 Karo et al. Jun 2006 A1
20060155317 List Jul 2006 A1
20060161078 Schraga Jul 2006 A1
20060178600 Kennedy et al. Aug 2006 A1
20060189908 Kennedy Aug 2006 A1
20060200044 Freeman et al. Sep 2006 A1
20060204399 Freeman et al. Sep 2006 A1
20060224172 LeVaughn et al. Oct 2006 A1
20060229533 Hoenes et al. Oct 2006 A1
20060241517 Fowler et al. Oct 2006 A1
20060257993 Mcdevitt et al. Nov 2006 A1
20060259102 Slatkine Nov 2006 A1
20060264996 LeVaughn et al. Nov 2006 A1
20060281187 Emery et al. Dec 2006 A1
20070016104 Jansen et al. Jan 2007 A1
20070017824 Rippeth et al. Jan 2007 A1
20070078313 Emery et al. Apr 2007 A1
20070078358 Escutia et al. Apr 2007 A1
20070083131 Escutia et al. Apr 2007 A1
20070100255 Boecker et al. May 2007 A1
20070112281 Olson May 2007 A1
20070179404 Escutia et al. Aug 2007 A1
20070179405 Emery et al. Aug 2007 A1
20070253531 Okuzawa et al. Nov 2007 A1
20070255181 Alvarez-icaza et al. Nov 2007 A1
20070255302 Koeppel et al. Nov 2007 A1
20080046831 Imai et al. Feb 2008 A1
20080077048 Escutia et al. Mar 2008 A1
20080139910 Mastrototaro Jun 2008 A1
20080194934 Ray et al. Aug 2008 A1
20080255598 LeVaughn et al. Oct 2008 A1
20080269625 Halperin et al. Oct 2008 A1
20080274447 Mecklenburg Nov 2008 A1
20090054810 Zanzucchi et al. Feb 2009 A1
20090156923 Power et al. Jun 2009 A1
20090292489 Burke et al. Nov 2009 A1
20090301899 Hodges et al. Dec 2009 A1
20100010374 Escutia et al. Jan 2010 A1
20100021947 Emery et al. Jan 2010 A1
20100021948 Lipman et al. Jan 2010 A1
20100095229 Dixon et al. Apr 2010 A1
20100152660 Mack et al. Jun 2010 A1
20100174211 Frey et al. Jul 2010 A1
20100185120 Sacherer et al. Jul 2010 A1
20100217155 Poux et al. Aug 2010 A1
20100249652 Rush et al. Sep 2010 A1
20100331650 Batman et al. Dec 2010 A1
20110098599 Emery et al. Apr 2011 A1
20110105872 Chickering, III et al. May 2011 A1
20110201909 Emery et al. Aug 2011 A1
20110294152 Lipman et al. Dec 2011 A1
20120166090 Lipman et al. Jun 2012 A1
20120296179 Zanzucchi et al. Nov 2012 A1
20130110516 Abulhaj et al. May 2013 A1
20130158430 Aceti et al. Jun 2013 A1
20130158432 Escutia et al. Jun 2013 A1
20130172698 Reynolds et al. Jul 2013 A1
20130274568 Escutia et al. Oct 2013 A1
20130274579 Richter et al. Oct 2013 A1
20140316301 Escutia et al. Oct 2014 A1
20140336480 Escutia et al. Nov 2014 A1
20140376762 Lipman et al. Dec 2014 A1
20150037898 Baldus et al. Feb 2015 A1
20150153351 Lipman et al. Jun 2015 A1
20150182157 Boriah et al. Jul 2015 A1
20150212006 Emery et al. Jul 2015 A1
20150268228 Schulat et al. Sep 2015 A1
20150335272 Natale et al. Nov 2015 A1
20160011178 Hoenes et al. Jan 2016 A1
20160038066 Escutia et al. Feb 2016 A1
20160256106 Krasnow et al. Sep 2016 A1
20160367178 Emery et al. Dec 2016 A1
20160374603 Shaanan et al. Dec 2016 A1
20170319121 Aceti et al. Nov 2017 A1
20170354355 Emery et al. Dec 2017 A1
20180008178 Escutia et al. Jan 2018 A1
20180214059 Escutia et al. Aug 2018 A1
20180296143 Anderson et al. Oct 2018 A1
20180338713 Polsky et al. Nov 2018 A1
20190000365 Beyerlein et al. Jan 2019 A1
20190025318 Lipman et al. Jan 2019 A1
20190104976 Reynolds et al. Apr 2019 A1
20190175086 Yang Jun 2019 A1
20190209064 Emery et al. Jul 2019 A1
20190209820 Chickering, III et al. Jul 2019 A1
20190269358 Messerschmidt Sep 2019 A1
20190274607 Krasnow et al. Sep 2019 A1
20190391129 Lipman et al. Dec 2019 A1
Foreign Referenced Citations (217)
Number Date Country
2 201 530 Sep 1997 CA
2 513 465 Aug 2004 CA
197 05 091 Feb 1999 DE
199 22 413 Nov 2000 DE
103 02-501 Aug 2004 DE
0 103 426 Mar 1984 EP
0 256 806 Feb 1988 EP
0 160 708 Oct 1989 EP
0 356 418 Feb 1990 EP
0 396 016 Nov 1990 EP
0 396 016 Nov 1990 EP
0 397 424 Nov 1990 EP
0 409 032 Jan 1991 EP
0 255 338 Feb 1998 EP
0 849 584 Jun 1998 EP
0 877 250 Nov 1998 EP
1 037 048 Sep 2000 EP
1 060 768 Dec 2000 EP
1 118 856 Jul 2001 EP
1 266 607 Dec 2002 EP
1 266 607 Dec 2002 EP
1 369 688 Oct 2003 EP
1 369 688 Oct 2003 EP
1 360 934 Nov 2003 EP
1 360 934 Nov 2003 EP
1 486 766 Dec 2004 EP
1 486 766 Dec 2004 EP
1 529 489 May 2005 EP
1 529 489 May 2005 EP
1 769 735 Apr 2007 EP
61-290342 Dec 1986 JP
63-305841 Dec 1988 JP
1-318963 Dec 1989 JP
3-63570 Mar 1991 JP
03093189 Apr 1991 JP
7-67861 Mar 1995 JP
7-213925 Aug 1995 JP
9-168530 Jun 1997 JP
9-313465 Sep 1997 JP
9-266889 Oct 1997 JP
9-294737 Nov 1997 JP
10-024028 Jan 1998 JP
10-505258 May 1998 JP
10-508518 Aug 1998 JP
10-318970 Dec 1998 JP
11-056822 Mar 1999 JP
11-281779 Oct 1999 JP
2000-116629 Apr 2000 JP
2000-126161 May 2000 JP
2000-168754 Jun 2000 JP
2000-254111 Sep 2000 JP
2001-159618 Jun 2001 JP
2001-515203 Sep 2001 JP
2001-281242 Oct 2001 JP
2001-305096 Oct 2001 JP
2001-330581 Nov 2001 JP
2002-502045 Jan 2002 JP
2002-085384 Mar 2002 JP
2002-514453 May 2002 JP
2002-168862 Jun 2002 JP
2003-507719 Feb 2003 JP
2003-108679 Apr 2003 JP
2003-180417 Jul 2003 JP
2004-000598 Jan 2004 JP
2004-500948 Jan 2004 JP
2004-117339 Apr 2004 JP
2004-202256 Jul 2004 JP
2004-209266 Jul 2004 JP
2004-519302 Jul 2004 JP
2004-522500 Jul 2004 JP
2004-528936 Sep 2004 JP
2005-503538 Feb 2005 JP
2005-087613 Apr 2005 JP
2006-512969 Apr 2005 JP
3638958 Apr 2005 JP
2005-525149 Aug 2005 JP
2005-237938 Sep 2005 JP
2005-525846 Sep 2005 JP
2005-527254 Sep 2005 JP
2006-506185 Feb 2006 JP
2006-512974 Apr 2006 JP
2006-516723 Jul 2006 JP
2006-521555 Sep 2006 JP
2006-527013 Nov 2006 JP
2007-014381 Jan 2007 JP
2007-054407 Mar 2007 JP
2007-067698 Mar 2007 JP
2007-136198 Jun 2007 JP
2007-521031 Aug 2007 JP
2007-311196 Nov 2007 JP
2007-537804 Dec 2007 JP
2008-125813 Jun 2008 JP
100458978 May 2005 KR
WO-8605966 Oct 1986 WO
WO-8800812 Feb 1988 WO
WO-8807666 Oct 1988 WO
WO-9114212 Sep 1991 WO
WO-9413203 Jun 1994 WO
WO-9510223 Apr 1995 WO
WO-9510223 Apr 1995 WO
WO-9604857 Feb 1996 WO
WO-9607907 Mar 1996 WO
WO-9614026 May 1996 WO
WO-9625088 Aug 1996 WO
WO-9704707 Feb 1997 WO
WO-9715227 May 1997 WO
WO-9729847 Aug 1997 WO
WO-9730344 Aug 1997 WO
WO-9741421 Nov 1997 WO
WO-9742885 Nov 1997 WO
WO-9742888 Nov 1997 WO
WO-9743962 Nov 1997 WO
WO-9800193 Jan 1998 WO
WO-9831275 Jul 1998 WO
WO-9835225 Aug 1998 WO
WO-9912008 Mar 1999 WO
WO-9923492 May 1999 WO
WO-9944508 Sep 1999 WO
WO-9956954 Nov 1999 WO
WO-9958051 Nov 1999 WO
WO-0009184 Feb 2000 WO
WO-0013573 Mar 2000 WO
WO-0014269 Mar 2000 WO
WO-0014535 Mar 2000 WO
WO-0018449 Apr 2000 WO
WO-0018449 Apr 2000 WO
WO 0019185 Apr 2000 WO
WO-0036400 Jun 2000 WO
WO-0042422 Jul 2000 WO
WO-0074763 Dec 2000 WO
WO-0074763 Dec 2000 WO
WO-0078208 Dec 2000 WO
WO-0113795 Mar 2001 WO
WO-0116575 Mar 2001 WO
WO-0152727 Jul 2001 WO
WO-0164105 Sep 2001 WO
WO-0164105 Sep 2001 WO
WO-0172220 Oct 2001 WO
WO-0180728 Nov 2001 WO
WO-0185233 Nov 2001 WO
WO-0185233 Nov 2001 WO
WO-0191634 Dec 2001 WO
WO-0191634 Dec 2001 WO
WO-0200101 Jan 2002 WO
WO-0200101 Jan 2002 WO
WO-0249507 Jun 2002 WO
WO-0249509 Jun 2002 WO
WO-0249509 Jun 2002 WO
WO-02078533 Oct 2002 WO
WO-02078533 Oct 2002 WO
WO-02082052 Oct 2002 WO
WO-02082052 Oct 2002 WO
WO-02093144 Nov 2002 WO
WO-02100251 Dec 2002 WO
WO-02100251 Dec 2002 WO
WO-02101359 Dec 2002 WO
WO-02101359 Dec 2002 WO
WO-2003030984 Apr 2003 WO
WO-2003066128 Aug 2003 WO
WO-2003066128 Aug 2003 WO
WO-2003070099 Aug 2003 WO
WO-2003071940 Sep 2003 WO
WO-2003071940 Sep 2003 WO
WO-03088834 Oct 2003 WO
WO-2004045375 Jun 2004 WO
WO-2004045375 Jun 2004 WO
WO-2004062499 Jul 2004 WO
WO-2004062500 Jul 2004 WO
WO-2004062500 Jul 2004 WO
WO-2004064636 Aug 2004 WO
WO-2004091693 Oct 2004 WO
WO-2004091693 Oct 2004 WO
WO-2004105827 Dec 2004 WO
WO-2004105827 Dec 2004 WO
WO-2005006939 Jan 2005 WO
WO-2005006939 Jan 2005 WO
WO-2005009238 Feb 2005 WO
WO-2005013824 Feb 2005 WO
WO-2005018709 Mar 2005 WO
WO-2005018709 Mar 2005 WO
WO-2005018710 Mar 2005 WO
WO-2005018710 Mar 2005 WO
WO-2005054840 Jun 2005 WO
WO-2005084543 Sep 2005 WO
WO-2005084546 Sep 2005 WO
WO-2005084546 Sep 2005 WO
WO-2005085995 Sep 2005 WO
WO 2005090969 Sep 2005 WO
WO-2005112763 Dec 2005 WO
WO-2006031920 Mar 2006 WO
WO-2006138226 Dec 2006 WO
WO-2006138226 Dec 2006 WO
WO-2007041062 Apr 2007 WO
WO-2007041062 Apr 2007 WO
WO-2007041063 Apr 2007 WO
WO-2007041063 Apr 2007 WO
WO-2007041244 Apr 2007 WO
WO-2007041244 Apr 2007 WO
WO-2007041287 Apr 2007 WO
WO-2007041287 Apr 2007 WO
WO-2007041355 Apr 2007 WO
WO-2007041355 Apr 2007 WO
WO-2007054317 May 2007 WO
WO-2007108519 Sep 2007 WO
WO-2007112034 Oct 2007 WO
WO-2007112034 Oct 2007 WO
WO-2008027319 Mar 2008 WO
WO-2008027319 Mar 2008 WO
WO-2008062648 May 2008 WO
WO-2009145920 Dec 2009 WO
WO-2009148624 Dec 2009 WO
WO-2009148626 Dec 2009 WO
WO-2011065981 Jun 2011 WO
WO-2011162823 Dec 2011 WO
WO-2013020103 Feb 2013 WO
WO-2014205412 Dec 2014 WO
WO-2018191700 Oct 2018 WO
Non-Patent Literature Citations (184)
Entry
ADA Consensus Development Panel. (Jan.-Feb. 1987). “Consensus Statement on Self-Monitoring of Blood Glucose,” Diabetes Care 10(1):95-99.
ADA (Jan. 1994). “Self-Monitoring of Blood Glucose,” Consensus Statement Diabetes Care 17(1):81-86.
Advisory Action dated Feb. 2, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 3 pages.
Advisory Action dated Apr. 8, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 3 pages.
Anonymous. (Sep. 30, 1993). “The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes Mellitus.” The New England Journal of Medicine 329(14):977-986.
Anonymous. (Jun. 23, 1998). Taking the “Ouch” Out of Needles: Arrays of “Microneedles” Offer New Techniques for Drug Delivery, Science Daily, located at <http:www.sciencedaily.com/releases/1998/06/980623045850.htm>, last visited Jan. 14, 2014, 3 pages.
Beregszàszi, M. et al. (Jul. 1997). “Nocturnal Hypoglycemia in Children and Adolescents with Insulin-Dependent Diabetes Mellitus: Prevalence and Risk Factors,” J. Pediatrics 131(1 Pt. 1):27-33.
Brazzle, J. et al. Active Microneedles with Integrated Functionality, Solid-State Sensor and Actuator Workshop, Hilton Head Island, South Carolina, Jun. 4-8, 2000, Technical Digest, 199-202.
Burge, M.R., (Aug. 2001). “Lack of Compliance with Home Blood Glucose Monitoring Predicts Hospitalization in Diabetes”, Diabetes Care 24(8): 1502-1503.
Chase, H.P. et al. (Feb. 2001). “Continuous Subcutaneous Glucose Monitoring in Children with Type 1 Diabetes,” Pediatrics 107(2):222-226.
Clarke, W.L. et al. (Sep.-Oct. 1981). “Evaluation of a New Reflectance Photometer for Use in Home Blood Glucose Monitoring,” Diabetes Care, 4(5):547-550.
Clarke, W.L. et al. (Sep.-Oct. 1987). “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose,” Diabetes Care 10(5):622-628.
Collison, M.E. et al. (Sep. 1999). “Analytical Characterization of Electrochemical Biosensor Test Strips for Measurement of Glucose in Low-Volume Interstitial Fluid Samples,” Clinical Chemistry 45(9):1665-1673.
Coster, S. et al. (2000). “Monitoring Blood Glucose Control in Diabetes Mellitus: A Systematic Review.” Health Technology Assessment 4(12):1-93.
Cox, D.J. et al. (Jun. 1997). “Understanding Error Grid Analysis,” Diabetes Care 20(6):911-912.
D'Arrigo, T.D. (Mar. 2000). “GlucoWatch Monitor Poised for Approval,” Diabetes Forecast, 53(3):43-44.
Extended European Search Report dated Jan. 22, 2013, for EP Application No. 12182900.6, filed on Sep. 29, 2006, 6 pages.
Extended European Search Report dated Feb. 22, 2012, for EP Application No. EP 10 18 1155, filed Sep. 28, 2010, six pages.
Extended European Search Report dated Jul. 18, 2013, for EP Application No. 06 772 943.4, filed on Jun. 13, 2006, 7 pages.
Extended European Search Report dated Nov. 8, 2016, for EP Application No. 16 167 087.2, filed on Aug. 3, 2012, 6 pages.
Extended European Search Report dated Apr. 19, 2011, for EP Application No. 10 18 0848.3 filed Sep. 28, 2010, 5 pages.
Extended European Search Report dated Apr. 29, 2013 for EP Patent Application No. 12192620.8, filed on Nov. 14, 2012, 8 pages.
Extended European Search Report dated Feb. 2, 2016 for European Patent Application No. 15187274.4, filed on Sep. 29, 2015, 5 pages.
Feldman, B. et al. (2000). “FreeStyle™: A Small-Volume Electrochemical Glucose Sensor for Home Blood Glucose Testing,” Diabetes Technology and Therapeutics, 2(2):221-229.
Final Office Action dated Jul. 9, 2008, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 19 pages.
Final Office Action dated Nov. 23, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 20 pages.
Final Office Action dated Jan. 21, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 7 pages.
Final Office Action dated Aug. 15, 2013 for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 12 pages.
Final Office Action dated Apr. 13, 2016, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 31 pages.
Final Office Action dated Aug. 28, 2014, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 11 pages.
Final Office Action dated Dec. 26, 2014, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 9 pages.
Final Office Action dated Jan. 22, 2014, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 8 pages.
Final Office Action dated Jun. 30, 2010, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 11 pages.
Final Office Action dated May 30, 2007, for U.S. Appl. No. 11/125,107, filed May 10, 2005, 11 pages.
Final Office Action dated Nov. 1, 2010, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 9 pages.
Final Office Action dated Nov. 21, 2011, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 8 pages.
Final Office Action dated Jun. 11, 2010, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 16 pages.
Final Office Action dated Mar. 10, 2015, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 24 pages.
Final Office Action dated Oct. 15, 2009, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 13 pages.
Final Office Action dated Aug. 14, 2012, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Final Office Action dated Sep. 23, 2013, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Final Office Action dated Mar. 5, 2009, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 17 pages.
Final Office Action dated Mar. 3, 2011, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 25 pages.
Final Office Action dated Jan. 6, 2016, for U.S. Appl. No. 14/321,631, filed Jul. 1, 2014, 9 pages.
Hemmerich, K.J. et al. (Apr. 1995).“Guide to Engineering Thermoplastics,” Medical Devices and Diagnostic Industry pp. 39-59.
International Search Report dated Aug. 16, 2007 for PCT Application No. PCT/US2006/038163, filed on Sep. 29, 2006, 1 page.
International Search Report dated Dec. 3, 2004, for PCT Application No. PCT/US2004/08798, filed on Mar. 24, 2004, 3 pages.
International Search Report dated May 2, 2007, for PCT Application No. PCT/US2006/37923, filed on Sep. 9, 2006, 1 page.
International Search Report dated Aug. 17, 2007 for PCT/US2006/38049, filed on Sep. 29, 2006, 1 page.
International Search Report dated Oct. 19, 2012 for PCT Application No. PCT/US2012/049629, filed on Aug. 3, 2012, 4 pages.
International Search Report dated Jan. 16, 2008, for PCT Application No. PCT/US2006/022840, filed on Jun. 13, 2006, 1 page.
International Search Report dated Aug. 20, 2007 for PCT Application No. PCT/US2006/37245, filed on Sep. 26, 2006, 1 page.
Interview Summary dated Jan. 13, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 4 pages.
Interview Summary dated Nov. 1, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 3 pages.
Interview Summary dated May 17, 2012, for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 3 pages.
Interview Summary dated May 17, 2012, for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 3 pages.
Interview Summary dated Aug. 27, 2012, for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 3 pages.
Interview Summary dated Aug. 27, 2012, for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 3 pages.
INTEG. (2000). “LifeGuide™ Glucose Meter. No Lancets. No Blood,” located at <http://www.integonline.com>, last visited May 1, 2000, 10 pages.
Ishii H. et al., (Aug. 2001). “Seasonal Variation of Glycemic Control in Type 2 Diabetic Patients”, Diabetes Care 24(8):1503.
Johnson, R.N. et al. (Jan. 1998). “Accuracy of Devices Used for Self-Monitoring of Blood Glucose,” Annals of Clinical Biochemistry 35(1):68-74.
Johnson, R.N. et al. (Jan. 1999). “Analytical Error of Home Glucose Monitors: A Comparison of 18 Systems,” Annals of Clinical Biochemistry 36(1):72-79.
Johnson, R.N. et al. (2001). “Error Detection and Measurement in Glucose Monitors,” Clinica Chimica Acta 307:61-67.
Kumetrix, Inc. (Dec. 1999). “Painless Blood Glucose Monitoring, Courtesy of the Mosquito,” Start-Up pp. 27-28.
Lee, S-C.(Jun. 1999). “Light Scattering by Closely Spaced Parallel Cylinders Embedded in a Finite Dielectric Slab,” Journal of the Optical Society of America A 16(6):1350-1361.
Mahler, R.J. et al. (1999). “Clinical Review 102, Type 2 Diabetes Melitus: Update on Diagnosis Pathophysiology, and Treatment,” The Journal of Clinical Endocrinology and Metabolism 84(4):1165-1171.
Massey V. et al. (Aug. 1960). “Studies on the Reaction Mechanism of Lipoyl Dehydrogenase” Biochim. Biophys. Acta 48: 33-47.
McGarraugh, G. et al. (2001). “Physiological Influences on Off-Finger Glucose Testing,” Diabetes Technology & Therapeutics 3(3):367-376.
McNichols, R.J. et al. (Jan. 2000). “Optical Glucose Sensing in Biological Fluids: An Overview,” Journal of Biomedical Optics, 5(1):5-16.
Medline Plus. (Jun. 17, 2008). , Medical Encyclopedia, Monitor Blood Glucose-Series: Part 1-4, 6 pages.
Neeley, W.E. et al. (1981). “An Instrument for Digital Matrix Photometry,” Clinical Chemistry 27(10):1665-1668.
Neeley, W.E. (1983). “Reflectance Digital Matrix Photometry,” Clinical Chemistry 29(6):1038-1041.
Neeley, W.E. (1983). “Multilayer Film Analysis for Glucose in 1-μL Samples of Plasma,” Clinical Chemistry 29(12):2103-2105.
Neeley, W.E. (1988). “A Reflectance Photometer with a Square Photodiode Array Detector for Use on Multilayer Dry-Film Slides,” Clinical Chemistry 34(11):2367-2370.
Non-Final Office Action dated Dec. 12, 2007, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 13 pages.
Non-Final Office Action dated Apr. 28, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 21 pages.
Non-Final Office Action dated Jun. 4, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 23 pages.
Non-Final Office Action dated Mar. 23, 2012, for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 7 pages.
Non-Final Office Action dated Mar. 23, 2012, for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 6 pages.
Non-Final Office Action dated Nov. 26, 2012 for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 9 pages.
Non Final Office Action dated Apr. 8, 2015, for U.S. Appl. No. 13/566,886, filed Aug. 3, 2012, 11 pages.
Non-Final Office Action dated Mar. 19, 2009, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 15 pages.
Non-Final Office Action dated Sep. 1, 2010, for U.S. Appl. No. 11/239,122, filed Sep. 30, 2005, 15 pages.
Non Final Office Action dated Apr. 12, 2011, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 7 pages.
Non-Final Office Action dated Sep. 13, 2011, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Non-Final Office Action dated Feb. 28, 2013, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 12 pages.
Non-Final Office Action dated Apr. 10, 2014, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 14 pages.
Non-Final Office Action dated May 29, 2015, for U.S. Appl. No. 14/614,177, filed Feb. 4, 2015, 13 pages.
Non Final Office Action dated Aug. 5, 2014, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 8 pages.
Non Final Office Action dated Dec. 5, 2014, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 7 pages.
Non Final Office Action dated Jan. 12, 2009, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 9 pages.
Non Final Office Action dated Jan. 21, 2011, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 9 pages.
Non Final Office Action dated Jul. 13, 2010, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 11 pages.
Non Final Office Action dated Jul. 31, 2015, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 16 pages.
Non Final Office Action dated Mar. 21, 2014, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 12 pages.
Non Final Office Action dated Mar. 25, 2011, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 13 pages.
Non Final Office Action dated Mar. 5, 2010, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 8 pages.
Non Final Office Action dated May 14, 2008, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 9 pages.
Non Final Office Action dated May 16, 2013, for U.S. Appl. No. 13/669,366, filed Nov. 5, 2012, 8 pages.
Non Final Office Action dated May 5, 2005, for U.S. Appl. No. 10/131,268, filed Apr. 23, 2002, 8 pages.
Non Final Office Action dated Nov. 2, 2006, for U.S. Appl. No. 11/125,107, filed May 10, 2005, 10 pages.
Non Final Office Action dated Oct. 14, 2009, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 10 pages.
Non Final Office Action dated Oct. 3, 2008, for U.S. Appl. No. 10/722,074, filed Nov. 24, 2003, 10 pages.
Non-Final Office Action dated Dec. 17, 2015, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 6 pages.
Non Final Office Action dated Dec. 2, 2004, for U.S. Appl. No. 10/347,620, filed Jan. 22, 2003, 8 pages.
Non-Final Office Action dated Jan. 27, 2009, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 17 pages.
Non-Final Office Action dated Jan. 6, 2014, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 12 pages.
Non-Final Office Action dated Jun. 21, 2013, for U.S. Appl. No. 13/752,261, filed Jan. 28, 2013, 12 pages.
Non-Final Office Action dated Jun. 6, 2008, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 17 pages.
Non-Final Office Action dated Oct. 9, 2014, for U.S. Appl. No. 14/446,262, filed Jul. 29, 2014, 15 pages.
Non Final Office Action dated Sep. 29, 2004, for U.S. Appl. No. 10/394,230, filed Mar. 24, 2003, 10 pages.
Non-Final Office Action dated Nov. 1, 2007, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 15 pages.
Non-Final Office Action dated Apr. 15, 2010, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 19 pages.
Non-Final Office Action dated Sep. 19, 2013, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 24 pages.
Non-Final Office Action dated Aug. 8, 2014, for U.S. Appl. No. 14/321,631, filed Jul. 1, 2014, 11 pages.
Notice of Allowance dated Apr. 3, 2014, for U.S. Appl. No. 11/239,123, filed Sep. 30, 2005, 6 pages.
Notice of Allowance dated Apr. 18, 2012, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 8 pages.
Notice of Allowance dated Apr. 19, 2010, for U.S. Appl. No. 29/338,117, filed Jun. 4, 2009, 4 pages.
Notice of Allowance dated Aug. 3, 2012, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 5 pages.
Notice of Allowance dated Jan. 14, 2010, for U.S. Appl. No. 29/338,117, filed Jun. 4, 2009, 4 pages.
Notice of Allowance dated Jun. 29, 2012, for U.S. Appl. No. 11/311,667, filed Dec. 20, 2005, 5 pages.
Notice of Allowance dated Mar. 14, 2012, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 7 pages.
Notice of Allowance dated Mar. 31, 2005, for U.S. Appl. No. 10/394,230, filed Mar. 24, 2003, 10 pages.
Notice of Allowance dated May 15, 2008, for U.S. Appl. No. 11/125,107, filed May 10, 2005, 7 pages.
Notice of Allowance dated May 28, 2009, for U.S. Appl. No. 29/300,934, filed May 30, 2008, 4 pages.
Notice of Allowance dated May 28, 2009, for U.S. Appl. No. 29/300,933, filed May 30, 2008, 6 pages.
Notice of Allowance dated Nov. 23, 2011, for U.S. Appl. No. 12/222,724, filed Aug. 14, 2008, 7 pages.
Notice of Allowance dated Nov. 27, 2012, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 5 pages.
Notice of Allowance dated Nov. 29, 2005, for U.S. Appl. No. 10/131,268, filed Apr. 23, 2002, 6 pages.
Notice of Allowance dated Oct. 12, 2011, for U.S. Appl. No. 11/529,612, filed Sep. 29, 2006, 8 pages.
Notice of Allowance dated Feb. 23, 2015, for U.S. Appl. No. 14/446,262, filed Jul. 29, 2014, 8 pages.
Notice of Allowance dated Feb. 5, 2014, for U.S. Appl. No. 13/752,261, filed Jan. 28, 2013, 9 pages.
Notice of Allowance dated Jun. 15, 2009, for U.S. Appl. No. 10/722,074, filed Nov. 24, 2003, 6 pages.
Notice of Allowance dated Mar. 2, 2016, for U.S. Appl. No. 11/529,614, filed Sep. 29, 2006, 12 pages.
Notice of Allowance dated Mar. 28, 2005, for U.S. Appl. No. 10/347,620, filed Jan. 22, 2003, 6 pages.
Notice of Allowance dated Sep. 18, 2014, for U.S. Appl. No. 13/037,089, filed Feb. 28, 2011, 9 pages.
Notice of Allowance dated Feb. 16, 2016, for U.S. Appl. No. 14/614,177, filed Feb. 4, 2015, 7 pages.
Notice of Allowance dated May 3, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 12 pages.
Notice of Allowance dated Mar. 27, 2015, for U.S. Appl. No. 13/562,129, filed Jul. 30, 2012, 7 pages.
Otto, E. et al. (2000). “An Intelligent Diabetes Software Prototype: Predicting Blood Glucose Levels and Recommending Regimen Changes,” Diabetes Technology and Therapeutics 2(4):569-576.
Pfohl, M. et al. (2000). “Spot Glucose Measurement in Epidermal Interstitial Fluid—An Alternative to Capillary Blood Glucose Estimation,” Experimental and Clinical Endocrinology & Diabetes 108(1):1-4.
Princen, H.M. (May 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, I. Capillary Rise Between Two Cylinders,” Journal of Colloid and Interface Science 30(1):69-75.
Princen, H.M. (Jul. 1969). “Capillary Phenomena in Assemblies of Parallel Cylinders, II. Capillary Rise in Systems with More Than Two Cylinders,” Journal of Colloid and Interface Science 30(3):359-371.
Rebrin, K. et al. (Sep. 1999). “Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring,” American Journal of Physiology 277(3):E561-E571.
Request for Continued Examination filed on Feb. 4, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 2 pages.
Request for Continued Examination filed on Apr. 23, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 2 pages.
Response to Non-Final Office Action filed on Apr. 11, 2008, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 18 pages.
Response to Non-Final Office Action filed on Jul. 28, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 27 pages.
Response to Non-Final Office Action filed on Nov. 4, 2010 for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 18 pages.
Response to Non-Final Office Action filed on Aug. 23, 2012 for U.S. Appl. No. 13/197,592, filed Aug. 3, 2011, 7 pages.
Response to Non-Final Office Action filed on Aug. 23, 2012 for U.S. Appl. No. 13/197,603, filed Aug. 3, 2011, 7 pages.
Response to Final Office Action filed on Jan. 9, 2009, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 23 pages.
Response to Final Office Action filed on Mar. 23, 2010, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 25 pages.
Response to Final Office Action filed on Apr. 12, 2011, for U.S. Appl. No. 11/529,613, filed Sep. 29, 2006, 11 pages.
Rosen, S. (1999). “Road to New-Age Glucose Monitoring Still Rocky,” Diagnostic Insight, pp. 4-5, 12-13, 16.
Smart, W.H. et al. (2000). “The Use of Silicon Microfabrication Technology in Painless Glucose Monitoring, ” Diabetes Technology & Therapeutics 2(4):549-559.
Spielman, A. et al.(2001). Mosquito: A Natural History of Our Most Persistent and Deadly Foe, First Edition, Hyperion, New York, NY, 3 pages. (Table of Contents Only).
Sonntag, O. (1993). Ektachem. Dry Chemistry, Analysis With Carrier-Bound Reagents, Elsevier Science Publishers, 57 pages.
Straub F.B. (Mar. 1939). “Isolation and Properties of a flavoprotien from Heart Muscle Tissue”, Biochemical Journal 33: 787-792.
Svedman, C. et al. (Apr. 1999). “Skin Mini-Erosion Technique for Monitoring Metabolites in Interstitial Fluid: Its Feasibility Demonstrated by OGTT Results in Diabetic and Non-Diabetic Subjects,” Scand. J. Clin. Lab. Invest. 59(2):115-123.
Tietz, N.W. (1986). Textbook of Clinical Chemistry, W.B. Saunders Company, pp. 1533 and 1556.
Trinder, P. (1969). “Determination of Glucose in Blood Using Glucose Oxidase with an Alternate Oxygen Acceptor,” Annals of Clinical Biochemistry 6:24-28.
U.S. Precision Lens, Inc. (1983).The Handbook of Plastic Optics.
Wikipedia (2016). “Capillary action,” 7 pages.
Written Opinion dated Aug. 16, 2007 for PCT Application No. PCT/US2006/038163, filed on Sep. 29, 2006, 4 pages.
Written Opinion dated Dec. 3, 2004, for PCT Application No. PCT/US2004/08798, filed on Mar. 24, 2004, 4 pages.
Written Opinion dated May 2, 2007, for PCT Application No. PCT/US2006/37923, filed on Sep. 9, 2006, 5 pages.
Written Opinion dated Aug. 17, 2007 for PCT/US2006/38049, filed on Sep. 29, 2006, 6 pages.
Written Opinion dated Oct. 19, 2012 for PCT Application No. PCT/US2012/049629, filed on Aug. 3, 2012, 7 pages.
Written Opinion of the International Searching Authority dated Jan. 16, 2008, for PCT Application No. PCT/US2006/022840, filed on Jun. 13, 2006, 3 pages.
Written Opinion dated Aug. 20, 2007 for PCT Application No. PCT/US2006/37245, filed on Sep. 26, 2006, 7 pages.
Yum, S. I. et al. (Nov. 1, 1999). “Capillary Blood Sampling for Self-Monitoring of Blood Glucose,” Diabetes Technology & Therapeutics, 1(1):29-37.
Non-Final Office Action dated May 15, 2017, by The United States Patent and Trademark Office for U.S. Appl. No. 14/743,867, filed Jun. 18, 2015.
Notice of Allowance dated Aug. 18, 2017, for U.S. Appl. No. 13/566,886, filed Aug. 3, 2012, 10 pages.
Notice of Allowance dated Aug. 4, 2017, by The United States Patent and Trademark Office for U.S. Appl. No. 14/743,867, filed Jun. 18, 2015, 7 pages.
Final Office Action dated Nov. 29, 2017, for U.S. Appl. No. 15/177,041, filed Jun. 8, 2016, 13 pages.
Non-Final Office Action dated Jan. 11, 2017, for U.S. Appl. No. 14/321,631, filed Jul. 1, 2014, 17 pages.
Non-Final Office Action dated Aug. 24, 2017, for U.S. Appl. No. 14/321,631, filed Jul. 1, 2014, 15 pages.
Final Office Action dated Mar. 21, 2018, for U.S. Appl. No. 14/321,631, filed Jul. 1, 2014, 18 pages.
Non-Final Office Action dated Mar. 20, 2017, for U.S. Appl. No. 15/191,434, filed Jun. 23, 2016, 20 pages.
Non-Final Office Action dated Jun. 26, 2017, for U.S. Appl. No. 15/191,434, filed Jun. 23, 2016, 17 pages.
Final Office Action dated Dec. 20, 2017, for U.S. Appl. No. 15/191,434, filed Jun. 23, 2016, 19 pages.
Notice of Allowance dated Jul. 20, 2018, for U.S. Appl. No. 15/177,041, filed Jun. 8, 2016, 11 pages.
Khalil, “Non-invasive glucose measurement technologies: an update from 1999 to the dawn of the new millennium,” Diabetes Technology & Therapeutics., vol. 6, No. 5, 2004.
Related Publications (1)
Number Date Country
20180310865 A1 Nov 2018 US
Provisional Applications (1)
Number Date Country
60721966 Sep 2005 US
Divisions (1)
Number Date Country
Parent 11529613 Sep 2006 US
Child 11941403 US
Continuations (5)
Number Date Country
Parent 14743867 Jun 2015 US
Child 15829835 US
Parent 14446262 Jul 2014 US
Child 14743867 US
Parent 13752261 Jan 2013 US
Child 14446262 US
Parent 13197592 Aug 2011 US
Child 13752261 US
Parent 11941403 Nov 2007 US
Child 13197592 US